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The NF-κB family is a central player in coordinating both innate and 
adaptive immunity and is involved in the regulation of a broad array of genes in 
response to diverse stimuli. The NF-κB family also plays a key role in the 
initiation and development of asthma. Because the NF-κB transcription factors are 
central to both normal biological functions and pathological conditions, absolute 
inhibition of NF-κB per se may not be a safe approach. Rather, appropriate and 
specific inhibition of signaling molecules that regulate NF-κB activity may be an 
effective anti-inflammatory strategy for asthma. The objectives of my thesis 
project were to examine the potential anti-inflammatory effects of a GSK-3β 
inhibitor, namely TDZD-8, and a herbal medicinal, namely andrographolide in a 
mouse asthma model and elucidate their mechanisms in the regulation of NF-κB 
pathway. 
BALB/c mice sensitized and challenged with ovalbumin developed allergic 
airway inflammation. Intravenous administration of TDZD-8 significantly (P < 
0.05) inhibited ovalbumin-induced increases in total cell counts, eosinophil counts, 
IL-5, IL-13, and eotaxin levels in bronchoalveolar lavage fluid, and OVA-IgE in 
serum. In addition, TDZD-8 reduced ovalbmuin-induced increase in mRNA levels 
of inflammatory molecules, infiltration of inflammatory cells, and mucus 
hypersecretion in lungs. TDZD-8 also suppressed airway hyperresponsiveness to 
methacholine in mice. Western blotting of the whole lung and human bronchial 
  
viii 
epithelial cell showed that TDZD-8 may exert its anti-inflammatory effects by 
inhibiting the phosphorylation of p65.  
Andrographolide attenuated inflammatory cell counts, IL-4, IL-5, IL-13, 
and eotaxin levels in bronchoalveolar lavage fluid, concentration of total IgE, 
OVA-IgE, OVA-IgG1 in the serum, and expression of inflammatory molecules in 
the lung, in a mouse asthma model. Andrographolide also suppressed OVA-
induced infiltration of inflammatory cells and mucus hypersecretion in the lungs, 
and OVA-induced airway hyperresponsiveness to methacholine. Western blotting 
and TransAM assay suggested that andrographolide may exert its anti-
inflammatory effects by inhibiting the phosphorylation of IKKβ and suppressing 
the DNA-binding activity of p65. 
Taken together, these present findings implicate that appropriate and 
specific inhibition of signaling molecules that regulate NF-κB pathway may have 
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1.1.1. Epidemiology of asthma 
Asthma is a common chronic disease which affects around 300 million people 
of all ages and ethnic backgrounds. The prevalence of asthma is high in 
industrialized countries such as United Kingdom (15.3%), New Zealand (15.1%), 
Australia (14.7%), and United States (10.9%) when compared with non-
industrialized countries, for instance, Mexico (3.3%), India (3%), and Iran (5.5%) 
(Masoli et al., 2004). A dramatic increase in the prevalence of asthma was 
reported in many countries from the 1960s to the 1990s (Eder et al., 2006). One 
popular theory which explains the rising prevalence of asthma today, especially in 
industrialized societies, is the “hygiene hypothesis”. This hypothesis contributes 
the rising prevalence of asthma to the decreasing infection rates in children due to 
cleaner environments in industrialized countries. It is derived from the observation 
that the risk of hay fever varies inversely with family size, and is further 
supported by the phenomenon that exposure to microbial products released by 
farm animals exerts a protective role against the development of asthma (Strachan, 
1989). Although asthma is generally not a life-threatening disease, mortality rates 
are still considerable, accounting for about 1 in every 250 deaths worldwide 
(Masoli et al., 2004). Furthermore, asthma is the third leading cause of 
hospitalization, exceeded only by pneumonia and injuries, among persons under 
18 years of age in the United States (Eder et al., 2006). High hospitalization fee, 
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together with high incidence, lead to asthma related costs exceeding those of 
tuberculosis and acquired immunodeficiency syndrome (AIDS) combined, 
accounting for 1% to 2% of the total health-care budget in industrialized countries 
(Braman, 2006). Furthermore, the economic burden of asthma disproportionately 
affects uncontrollable asthma patients. In both western and developing countries, 
10% to 20% uncontrollable asthma patients are responsible for approximately 
50% of direct or indirect costs, whereas 70% of mild asthma patients account for 
only 20% of total costs (Beasley, 2002; Braman, 2006). In summary, the rising 
prevalence, mortality, and high economic burden of asthma are having huge 
effects on the health-care systems worldwide. Therefore, more research should be 
done to better understand the pathophysiology of asthma and further explore 
potentially effective therapies for this disease.  
1.1.2. Susceptibility genes of asthma 
Both genetic background (atopy) and environmental factors (allergens, viruses, 
and occupational exposures) contribute to the initiation and development of 
asthma (Busse and Lemanske, 2001). In developed countries, 30% of the 
population is atopic, whereas only 10-12% of the population suffers from asthma, 
suggesting that allergic responses to inhaled allergens are considered as risky 
factors rather than causative factors of asthma (Hammad and Lambrecht, 2008). 
Therefore, it is critical to identify both genetic and environmental factors and their 
interactions that might contribute to the development of asthma in a sensitized 
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subject. It has been more than 10 years since the first genome-wide screen for 
asthma and atopy susceptibility loci (Ober and Hoffjan, 2006). In a decade, rapid 
advances in identifying susceptibility genes for asthma have uncovered numerous 
genes which are crucial to the pathogenesis of asthma (Table 1.1) (Vercelli, 2008). 
These asthma susceptibility genes are involved in probably all aspects of asthma 
including innate immunity and immunoregulation, T helper 2 (Th2) cell 
differentiation and effector function, epithelial biology and mucosal immunity, 
lung function, airway remodeling, and disease severity (Vercelli, 2008). Despite 
the apparent achievements in asthma genetics, there remain huge confusing 
discrepancies about the linkage between genotypes and phenotypes of asthma. 
Both gene-environment and gene-gene interactions might dramatically change the 
impact of a specific gene on the complex phenotypes, as are supported by 
epidemiological studies of asthma (Moffatt et al., 2007; Vercelli, 2008). Finally, 
understanding of asthma genetics not only helps us unravel the pathogenesis of 
this disease, but may also provide information for pharmacogenetic approaches, 
leading to individualization of treatments with high efficacy and low side effects 
for patients (Hall, 2006).  
1.1.3. Pathophysiology of asthma 
Asthma is a chronic airway disease which is characterized by airway 
inflammation, mucus hypersecretion, and airway hyperresponsiveness (AHR) 
(Figure 1.1) (Busse and Rosenwasser, 2003).  
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Table 1.1 Susceptibility genes identified for asthma (Adaped from Vercelli, 2008)  
Gene Chromosome Function and pathway 
GSTM1 1p13.3 Environmental and oxidative stress-detoxification 
FLG 1q21.3 Epithelial barrier integrity 
IL10 1q31-q32 Immunoregulation 
CTLA4 2q33 T-cell-response inhibition and immunoregulation 
IL-13 5q31 Th2 effector function 
IL-4 5q31.1 Th2 differentiation and IgE induction 
CD14 5q31.1 Innate immunity-microbial recognition 
SPINK5 5q32 Epithelial serine protease inhibitor 
ADRB2 5q31-q32 Bronchial smooth-muscle relaxation 
HAVCR1 5q33.2 T-cell-response regulation-HAV receptor  
LTC4S 5q35 Cysteinyl leukotriene biosynthesis, inflammation 
LTA 6q21.3 Inflammation 
TNF-α 6q21.3 Inflammation 
HLA-DRB1 6q21 Antigen presentation 
HLA-DQB1 6q21 Antigen presentation 
HLA-DPB1 6q21 Antigen presentation 
GPRA 7q14.3 Regulation of cell growth and neural mechanisms 
NAT2 8p22 Detoxification of drugs and carcinogens 
FCERIB 11q13 High-affinity Fc receptor for IgE 
CC16 11q12.3-q13.1 Epithelium-derived anti-inflammatory protein 
GSTP1 11q13 Environmental and oxidative stress, 
detoxification 
IL-18 11q22.2-q22.3 Induction of IFNγ and TNF 
STAT6 12q13 IL-4 and IL-13 signalling 
NOS1 12q24.2-q24.31 Nitric oxide synthesis — cell–cell communication 
CMA1 14q11.2 Mast-cell chymotryptic serine protease 
IL-4R 16p12.1-p12.2 α-chain of the IL-4 and IL-13 receptors 
CCL11 17q21.1-q21.2 Epithelium-derived eosinophil chemoattractant 
CCL5 17q11.2-q12 Monocyte, T-cell and eosinophil chemoattractant 
ACE 17q23.3 Inactivation of inflammatory mediators 
TBXA2R 19p13.3 Smooth-muscle contraction, inflammation 
TGFB1 19q13.1 Immunoregulation, cell proliferation 
ADAM33 20p13 Cell–cell and cell–matrix interactions 
















Figure 1.1 Schematic diagram of pathogenesis of asthma. Definition of 
abbreviations: ICAM-1 = intercellular adhesion molecule-1; TSLP = thymic 
stromal lymphopoietin; VCAM-1 = vascular cell adhesion molecule-1; VLA-4 = 










Inhaled allergens, often the initiator of the asthma, are taken up by lung dendritic 
cells (DC). Then, under the presence of low concentration toll-like receptor (TLR) 
agonist within the allergen itself or the presence of proteolytic activity within the 
allergen, DCs are activated and migrate to the draining lymph nodes where they 
present allergens to naïve CD4+ T cells, promoting the differentiation of naïve 
CD4+ T cells into Th2 cells (Hammad and Lambrecht, 2008). Th2 cells have a 
central role in the pathogenesis of asthma and produce an array of cytokines such 
as interleukin-4 (IL)-4, IL-5, IL-9, and IL-13. IL-4 is mainly responsible for the B 
cells isotype switching. Under the presence of IL-4, IL-13, and other molecules, B 
cells undergo isotype switching and synthesize IgE which is released into 
circulation, eventually binding to high affinity IgE receptors (FcεRΙ) on the 
surface of mast cells. Crosslinking of antigens, IgE, and FcεRΙ on mast cells lead 
to the degranulation of mast cells and the release of mediators including histamine, 
leukotrienes, and cytokines, causing acute bronchoconstriction (Busse and 
Lemanske, 2001). IL-5 is the most critical cytokine mediating the differentiation, 
activation, and survival of eosinophils, which may contribute to both 
inflammation and airway remodeling in asthma (Simon and Simon, 2007). IL-9 
could promote the proliferation of mast cells. Furthermore, IL-13 is the most 
pivotal effector of all Th2 cytokines, inducing almost all pathophysiological 
features of asthma comprising airway inflammation, AHR, mucus oversecretion, 
and airway remodeling (Wills-Karp, 2004). In addition, adhesion molecules, their 
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receptors, and chemokines are vital for the transmigration of inflammatory cells 
from circulation into inflammatory sites in response to allergic provocation 
(Rosenberg et al., 2007). Infiltration of inflammatory cells and the release of Th2 
cytokines may lead to transient and reversible AHR, whereas multiple structural 
changes in the airway, known as airway remodeling, could contribute to persistent 
AHR (Cockcroft and Davis, 2006).   
1.1.3.1.   Mast cells 
Mast cells arise from CD34+ pluripotent stem cells in the bone marrow, 
circulate in the blood as precursors, and then undergo tissue-specific maturation. 
In tissue, mast cells mature under the influence of stem cell factor (SCF) and its 
receptor CD117. In addition to SCF, mast cell growth and differentiation is 
manipulated by various cytokines, including IL-3, IL-4, IL-6, IL-9, IL-10, and 
nerve growth factor (Brown et al., 2008).  
Mast cells are activated by the crosslinking of FcεRΙ or by non-IgE-mediated 
pathways through complement receptors or toll-like receptors. Upon activation, 
mast cells release an array of mediators, cytokines, and chemokines. The pattern 
of mediator release is modulated by cytokines, growth factors, and the 
microenvironment (Brown et al., 2008). For instance, IL-4 could augment FcεRΙ-
mediated responses by mast cells (Bischoff et al., 1999), whereas, IL-10 and 
transforming growth factor-β (TGF-β), produced by regulatory T cells could 
diminish those reactions (Royer et al., 2001). 
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Mast cells release an array of mediators and cytokines which may induce 
inflammation, change airway smooth muscle (ASM) activity, lead to mucus 
hypersecretion, and cause Th2 polarization (Brown et al., 2008). Histamine, stored 
in the granules within mast cells, and lipid mediators such as leukotriene (LT)C4, 
LTD4, LTE4, and prostaglandin D2, all synthesized upon activation of mast cells, 
could induce contraction of ASM, causing bronchoconstriction. In addition, 
increased mast cells population, but not T cells or eosinophils population, was 
found in ASM of asthmatic patients (Brightling et al., 2002). Furthermore, 
activated mast cells produced growth factors (e.g. vascular endothelial growth 
factor [VEGF] and basic fibroblast growth factor [bFGF]), proteases, histamine, 
metalloproteinases, together with histamine and lipid mediators, could lead to 
proliferation and remodeling of epithelium and mucus hypersecretion. In addition, 
mucosal mast cells are recruited to the surface of epithelium by SCF, which has 
been shown to be overexpressed in the epithelium of asthmatic patients. Moreover, 
mast cell-derived cytokines such as IL-4, IL-5, IL-9, and IL-13 could lead to Th2 
differentiation, causing allergic inflammation. Mast cells may contribute to both 
the early-phase and the late-phase reaction in asthma (Barnes, 2008; Brown et al., 
2008).  
1.1.3.2.    Eosinophils 
Eosinophil progenitors also arise from pluripotent CD34+ stem cells in bone 
marrow. Under the regulation of three classes of transcription factors including 
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GATA-1(a zinc finger family member), PU.1 (an Eta family member), c/EBP 
(CCAAT/enhancer-binding protein family), and cytokines such as IL-3, IL-5, and 
granulocyte/macrophage colony-stimulating factor (GM-CSF), eosinophils 
progenitors  (CD34+IL-5R+) differentiate, mature and are released from the bone 
marrow into circulation where they represent 1% to 5% of the leukocytes. Under 
normal condition, the majority of eosinophils migrates into the gastrointestinal 
tract where they stay within the lamina propria of all segments except the 
esophagus (Hogan et al., 2008).  
Eosinophils are involved in a variety of inflammatory processes, such as 
allergic diseases, parasitic infections, tissue injury and tumor immunity (Simon 
and Simon, 2007). In particular, elevated eosinophil count in tissue, blood, and 
bone marrow is one of the hallmarks of asthma and is associated with disease 
severity, suggesting that eosinophils are one of many pivotal effector cells in the 
pathophysiology of asthma (Bousquet et al., 1990; Hogan et al., 2008). In 
response to allergic stimuli, eosinophils are attracted to the inflammatory sites by 
the orchestration of Th2 cytokines (IL-5, IL-13), adhesion molecules (intercellular 
adhesion molecule-1 [ICAM-1], vascular cell adhesion molecule-1 [VACM-
1] ,and selectin), chemokines(eotaxin-1,2,3, and regulated upon activation, normal 
T-cell expressed, and secreted [RANTES]), and other molecules (i.e. chitinases) 
(Rosenberg et al., 2007; Zhu et al., 2004). Of these cytokines, IL-5 is the most 
essential one which not only regulates the trafficking, but also the differentiation, 
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maturation, and survival of eosinophils. Eotaxins are eosinophil-specific 
chemokines which selectively regulate eosinophil trafficking through the C-C 
chemokine receptor (CCR)3 receptors, which are expressed predominantly on 
eosinophils. Briefly, eotaxin-1 is produced by epithelial cells upon stimulation by 
Th2 cytokines via signal transducer and activator of transcription (STAT)-6 
dependent pathways. Both eotaxin-2 and eotaxin-3 are expressed at later time 
points following challenge by allergens as compared to eotaxin-1. In addition, 
polymorphisms in genes encoding eotaxin-2 and eotaxin-3 have been related to 
the increased eosinophil population in asthmatic patients (Rosenberg et al., 2007). 
Furthermore, IL-5 could synergize with eotaxins to enhance mobilization of 
eosinophils into the lung following allergen exposure. 
At the inflammatory foci, eosinophils release numerous proinflammatory 
cytokines, lipid mediators (platelet-activating factor [PAF] and LTC4), and toxic 
granule proteins including major basic protein (MBP), eosinophil cationic protein 
(ECP), eosinophil-derived neurotoxin, and eosinophil peroxidase (Hogan et al., 
2008). Eosinophils exert their functions, as one of major effector cells in allergic 
reactions, by secreting these inflammatory molecules which contribute to  
upregulation of adhesion systems, modulation of cellular trafficking, regulation of 
vascular permeability, mucus hypersecretion, smooth muscle constriction, even 
tissue damage and dysfunction (Hogan et al., 2008). Eosinophils can also 
modulate immune functions as an antigen presenting cell (APC) in addition to its 
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function as effector cells (Rothenberg and Hogan, 2006).  In a mouse asthma 
model, eosinophils from allergic lungs expressed both classes of major 
histocompatibility complex (MHC)Ⅰand Ⅱ  peptides and T cell costimulatory 
molecules (CD80 and CD86), migrate to regional lymph nodes, and functioned as 
APCs to stimulate CD4+T cells. Blockade of CD80 and CD86 by monoclonal 
antibodies diminished eosinophil-dependent T cell proliferation and cytokine 
secretion (Shi, 2004). In addition, recent evidence has suggested that eosinophils 
may be involved in airway remodeling in asthma (Foley et al., 2007). Eosinophils 
are a significant source of profibrotic cytokines and fibrogenic mediators 
including TGF-β, IL-11, IL-17, TGF-α, and matrix metallopeptidase (MMP). In 
particular, TGF-β stimulates fibroblast to promote the synthesis and secretion of 
numerous proteins into the extracellular matrix. The thickening of the subepithelia 
basement membrane has also been shown to be related to the infiltration of 
eosinophils in bronchial mucus in severe asthma patients (Foley et al., 2007). 
Moreover, one study has shown that there are TLRs on human eosinophils, and 
peptidoglycan (TLR2 ligand), flagellin (TLR5 ligand), and imiquimod R837 
(TLR7 ligand) trigger both nuclear factor-κB (NF-κB) and mitogen-activated 
protein kinase (MAPK) pathways in eosinophils, leading to the release of IL-1β, 
IL-6, IL-8, GRO-α, superoxides, and ECP (Wong et al., 2007). This study 
provides a possible link between microbe-induced innate immunity and the 
exacerbation of asthma through activation of eosinophils. 
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Advances in the understanding of the eosinophil’s functions in the 
pathogenesis of asthma have suggested that therapies targeting eosinophil 
regulators (humanized anti-IL-5 and CCR3 antagonists) could be promising for 
asthma patients (Hogan et al., 2008). 
1.1.3.3.    T lymphocytes 
T lymphocytes constitute the majority of lung lymphocytes in normal 
individuals and are located within the airway, alveolar epithelium, and interstitium 
(Baraldo et al., 2007). Naïve T helper cells require two signals for activation. The 
first signal orginates from the interaction between the T-cell receptor (TCR) and 
peptide antigen-class ΙΙ MHC presented on APCs, and is followed immediately by 
the second signals by the interaction between costimulatory molecules such as 
CD28, B7, OX40, OX40L, etc. Then, activated T helper cells begin to divide into 
a specific clone of effector cells, comprising of Th1, Th2, regulatory T (Treg), and 
Th17, depending on their distinct cytokine-secretion phenotype and unique 
functions (Kaiko et al., 2008). In particular, Th2 cells, which secrete IL-4, IL-5, 
IL-9, and IL-13 and activate B cells, play a key role in the development of asthma 
(Georas et al., 2005).  
There are a broad array of mechanisms involved in Th2 polarization. When 
IL-4 binds to its receptor on the surface of  T cells, the receptor subunits move 
together and Janus kinase (JAK)1, and JAK3 are activated, leading to the 
dimerization and translocation of STAT-6 (Kaiko et al., 2008). In the nucleus, 
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STAT-6 activates the expression of zinc finger transcription factor GATA-3, 
which is necessary for Th2 polarization (Kaplan et al., 1996; Zheng and Flavell, 
1997). GATA-3 increases transcription of Th2 cytokines genes, selectively 
differentiates Th2 cells, and inhibits T-bet, a critical transcription factor for Th1 
cells (Zhu et al., 2006). In, addition, other transcription factors are also associated 
with Th2 differentiation. It has been shown that NF-κB regulates Th2 polarization 
by controlling the expression of GATA-3 (Das et al., 2001). c-MAF 
(musculoaponeurotic fibrosarcoma oncogene homolog), specific to Th2 cells, is 
responsible for the regulation of IL-4 synthesis (Ho et al., 1998). Nuclear factor of 
activated T-cells (NFAT) and activator protein-1 (AP-1) synergize to promote the 
expression of IL-4 (Georas et al., 2005). In addition to IL-4, IL-6 and IL-11 could 
induce Th2 cells polarization by stimulating the production of IL-4 and inhibiting 
the secretion of interferon (IFN)γ (Curti et al., 2001; Dodge et al., 2003). 
Furthermore, the inducible costimulatory protein (ICOS), a member of the CD28 
family, has been found to mediate Th2 responses by the enhancement of IL-4 
receptor signaling (Watanabe et al., 2005). The CD28 ligand can induce GATA-3 
and promote Th2 cells polarizatoin independent of IL-4 (Rodriguez-Palmero et al., 
1999).  
Th2 cells produce IL-4, IL-5, IL-9, and IL-13, contributing to the 
characteristic features of asthma (Baraldo et al., 2007). IL-4 is essential for 
driving the differentiation of naïve Th0 cells into Th2 cells (Kopf et al., 1993). IL-
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4 is also required for the activation and differentiation of B cells, and 
subsequently synthesis and secretion of IgE and IgG4 (IgG1 in the mouse) 
(Bonnefoy et al., 1996). In addition, IL-4 has been shown to regulate extracellular 
matrix proteins and collagen, suggesting it plays roles in airway remodeling in 
asthma (Liu et al., 2002; Postlethwaite et al., 1992). IL-5 was originally identified 
for its role in activating B cells (Takatsu et al., 1994). Now IL-5 has been 
recognized as the major regulator in the maturation, differentiation, and activation 
of eosinophils (Rothenberg and Hogan, 2006). IL-9 has been shown to be involved 
in airway inflammation, mucus hypersecretion, and AHR in asthma (Cheng et al., 
2002). IL-9 can also act on other cells such T cells, B cells and mast cells during 
the allergic responses (Soussi-Gounni et al., 2001). IL-13 is the most important 
Th2 effector cytokine, contributing to almost all characteristic features of asthma 
independent of other Th2 cytokines (Wills-Karp, 2004). Although the exact 
mechanisms by which IL-13 induces allergic reponses remain unknown, numerous 
studies have suggested the importance of IL-13 in the effector phase of asthma by 
regulating eosinophilic inflammation, isotype class swiching in B cells to IgE 
synthesis, induction of chemokines and adhesion molecules, subepithelial fibrosis, 
mucus hypersecretion, and AHR (Wills-Karp and Chiaramonte, 2003).   
In recent years, many distinct Treg cells, including CD8+ Treg cells, natural 
killer  (NK) T cells, and several different CD4+ Treg cells, have been identified as 
key players in immune tolerance (van Oosterhout and Bloksma, 2005). Of these 
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Treg cells, naturally occurring CD4+CD25+ Treg cells and IL-10-secreting CD4+ 
Treg cells have been shown to suppress the Th2 responses to allergen (Larche, 
2007). IL-10, the main cytokine secreted by these Treg cells, inhibits the 
activation of inflammatory cells including mast cells, eosinophils, APCs, and Th2 
cells. In addition, IL-10 enhances Ig isotype switching in B cells, which 
subsequently augment the IL-10-secreting CD4+ Treg cells (Hawrylowicz and 
O'Garra, 2005). Furthermore, the level of IL-10 has been shown to be related to 
the anti-inflammatory effects of glucocorticoid (Hawrylowicz and O'Garra, 2005).  
1.1.3.4.    B lymphocytes 
B lymphocytes originate from bone marrow, and then enter peripheral 
lymphoid organs where they differentiate through several transitional stages and 
eventually become mature B lymphocytes (Larosa and Orange, 2008). Terminally 
differentiated B lymphocytes are known as plasma cells which are essential for the 
production of a secreted Ig (Matthias and Rolink, 2005). A variety of nuclear 
factors such as E-box factors, early B-cell factors, and NF-κB, are involved in the 
development and functions of B lymphocytes (Matthias and Rolink, 2005). 
Especially, several stages of late B lymphocyte differentiation and maturation are 
influenced by some components of NF-κB pathway. For example, p50-deficient 
mice lack marginal zone B cells and c-Rel (v-rel reticuloendotheliosis viral 
oncogene homolog) deficient mice show reduced numbers of marginal zone B 
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cells (Cariappa et al., 2000). Furthermore, p50/p52 double knockout mice fail to 
generate mature B cells (Franzoso et al., 1997).  
B lymphocytes play an important role in the pathogenesis of asthma through 
production of Ig (Barnes, 2008). Under the influence of CD40 ligand and 
cytokines, mainly IL-4 and IL-13, B cells undergo immunoglobulin class 
switching to IgE. Following challenge by allergens, crosslinking of allergen-IgE 
complex with FcεRΙ on the surface of mast cells leads to mast cell degranulation 
and synthesis of lipid mediators, known as the early phase of the allergic response. 
IgE also binds to low affinity IgE receptor (FcεRΙΙ) expressed on other 
inflammatory cells, such as B cells, macrophages, and eosinophils, thereby 
augmenting allergic reactions. Furthermore, allergen-IgE complex binds to CD23, 
expressed by activated B cells, enhancing antigen presentation to T cells (Carlsson 
et al., 2007). Anti-IgE monoclonal antibody, omalizumab, has been shown to 
reduce airway inflammation and exacerbations in asthma patients (Avila, 2007). 
Besides the production of Ig, studies have suggested that B cells with B7 
costimulatory molecules might be necessary for the development of CD4+ effector 
cells in a polarized Th2 response in animal models (Liu et al., 2007). 
1.1.3.5. Epithelial cells 
Epithelial cells are essential in host defense and inflammation, bridging innate 
immune responses and adaptive immune responses including DC, T cells, and B 
























Figure 1.2 Roles of epithelium on innate and adaptive immunity (Adapted from 
Schleimer et al., 2007). Definition of abbreviations: TSLP = thymic stromal 
lymphopoietin; DC = dendritic cell; Bas = basophil; Eos = eosinophil; PAMP = 










The role of epithelium in innate immune response has been known for decades. 
Epithelium protects the airways from most microorganisms via secretion of 
numerous molecules including enzymes, peptides, protease inhibitors, various 
small molecules, etc (Schleimer et al., 2007). Epithelium serves as the main 
barrier for the airways; abnormal barrier function of the epithelium has been 
linked to high incidences of asthma, suggesting the role of epithelium dysfunction 
in asthma (Hudson, 2006).  
Besides being involved in innate immunity, epithelial cells play an even more 
important role in adaptive immunity, orchestrating asthmatic responses. 
Enzymatically active allergens stimulate epithelial cells, leading to the activation 
of NF-κB pathway, and production of chemokines (i.e. CCL17 and CCL20) and 
cytokines (i.e. GM-CSF, IL-6, IL-25, and thymic stromal lymphopoietin [TSLP]), 
which subsequently attract and activate DC, producing Th2 cells skewed 
responses (Hammad and Lambrecht, 2008). TSLP, a IL-7-like cytokine produced 
by epithelial cells in the airways, plays a central role in driving DC-mediated Th2 
cell response (Allakhverdi et al., 2007). Upon stimulation of epithelial cells by 
TLR ligands or IL-4, TSLP is released and interacts with DC, causing the 
upregulation of costimulatory molecules such as CD40, OX40, and CD80, and 
Th2 polarization (Holgate, 2007; Kato et al., 2007).In addition, TSLP has been 
shown to directly activate mast cells and cause the subsequent secretion of 
cytokines such as IL-5, IL-6, IL-13, and GM-CSF (Allakhverdi et al., 2007). 
 20 
Furthermore, the expression of TSLP is increased in the asthmatic airways and 
correlates with the severity of asthma (Ying et al., 2005). Besides DC and T cells, 
epithelial cells also produce several molecules, such as CCL28, IL-6, and TGF-β, 
which regulate the activation, differentiation, and migration of B cells (Schleimer 
et al., 2007). In addition, it has been shown that the NF-κB pathway airway in 
epithelial cells is essential for the lung inflammation in response to local or 
systemic stimuli, in transgenic mice express a constitutively active form of IKKβ 
under control of the epithelial-specific CC10 promoter (Cheng et al., 2007). 
1.1.3.6.    Mucus hypersecretion 
Different phenotypes of airway muscus hypersecretion, including luminal 
mucus overproduction, goblet cell hyperplasia, submucosal gland hypertrophy, 
and plasma exudation, are characteristic pathological features of asthma (Rogers, 
2004). Airway mucus contains about 2% mucin, a high-molecular-weight 
glycoprotein, which is secreted by goblet cells in epithelial and mucous cells in 
the submucosal glands (Finkbeiner, 1999; Rogers, 2003). Of the 19 human mucin 
genes identified to date, Muc5ac, Muc5b, and Muc2 gene products have been 
considered the major gel-forming mucins of the airways (Morcillo and Cortijo, 
2006).  
A wide array of exogenously inhaled allergens and endogenous mediators can 
induce mucus hypersecretion (Morcillo and Cortijo, 2006). Cumulative evidence 
has suggested that IL-13, which independently induces goblet cell hyperplasia 
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without IL-4 and IL-5, is probably the key regulator of mucus hypersecretion 
(Wills-Karp and Chiaramonte, 2003). IL-9, another Th2 cytokine, could also 
enhance mucus secretion. In addition, oxidant stresses are associated to increased 
mucin secretion. NF-E2-related factor-2 (Nrf2) is known to plays a crucial role in 
the regulation of many antioxidant genes. Nrf2 deficient asthmatic mice displayed 
amplified inflammatory responses including mucus cell hyperplasia (Rangasamy 
et al., 2005). Moreover, MMP-9, an asthma related protease, is involved in the 
elevation of Muc5ac expression via stimulation of epidermal growth factor 
receptor in human airway epithelial cells (Deshmukh et al., 2005; Ohbayashi and 
Shimokata, 2005).    
NF-κB pathway also plays an important role in mucus hyperserection in 
mouse asthmatic models (Desmet et al., 2004; Poynter et al., 2004). It has been 
reported that activated NF-κB could bind to the κB site in the 5`-flanking region 
of the Muc2 gene in of epithelial cells, leading to the transcription of Muc2 mucin 
(Li et al., 1998). In addition, tumor necrosis factor-α (TNF-α) promotes the 
transcription of Muc5ac and its products in airway epithelium through a NF-κB 
(IKK)β dependent mechanism (Lora et al., 2005). The contribution of NF-κB 
pathway to mucus production is further supported by a mouse asthma model with 
IKKβ deletion in the airway (Broide et al., 2005).  
1.1.3.7. Airway hyperresponsiveness 
 22 
AHR is a characteristic feature of asthma, although mechanisms of AHR in 
asthma remain unclear (Busse and Lemanske, 2001). There are at least two 
different components of AHR: the variable and persistant components (Cockcroft 
and Davis, 2006). The variable component of AHR is probably related to airway 
inflammation, reflecting the acute effects of airway inflammation, whereas the 
persistent component of AHR is likely associated with structural changes of the 
airways, known as airway remodeling, reflecting the chronic effects of airway 
inflammation (Cockcroft and Davis, 2006). However, AHR is such a complicated 
process that it is almost impossible to simply arbitrarily separate it into several 
distinct components. 
AHR is closely related to the inflammatory process of asthma. Upon 
activation by antigens, Th2 cells produce cytokines, including IL-4, IL-5, IL-9, 
and IL-13, which orchestrate the recruitment and activation of other inflammatory 
cells, such as mast cells and eosinophils, which contribute to the initiation of AHR 
(Wills-Karp, 1999). Blockade of IL-4 receptor has been shown to inhibit the 
allergen-induced AHR in mice and inhaled IL-4 induced AHR in response to 
methacholine in a human placebo-controlled study, indicating that IL-4 can 
increase AHR in asthma (Gavett et al., 1997; Shi et al., 1998). IL-5 is responsible 
for the differentiation, maturation, and activation of eosinophils, and plays a 
critical role in AHR by mobilizing and activating esoinophils, leading to the 
release of pro-inflammatory products such as major basic protein and cysteinyl-
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leukotrienes, which are closely associated with AHR (Rothenberg and Hogan, 
2006). IL-13, the major effector Th2 cytokine in asthma, can independently 
induce AHR in the absence of lymphocytes, mast cells, IL-4, and IL-5 (Grunig et 
al., 1998; Wills-Karp, 2004; Wills-Karp et al., 1998; Yang et al., 2001). Moreover, 
IL-13 may induce the contraction and proliferation of ASM cells, directly via IL-4 
receptor α chain or IL-13 receptor α1 and α2 chain expressed on ASM cells 
(Laporte et al., 2001; Moore et al., 2002), or indirectly via the stimulation of 
cysteinyl-leukotriene (Espinosa et al., 2003; Vargaftig and Singer, 2003) . Mast 
cells release mediators such as histamine, LTs, PAF, which cause microvascular 
leakage, increase mucus production, and induce bronchoconstriction (Wills-Karp, 
1999). Furthermore, mast cells contribute to airway remodeling, through direct 
interaction with ASM cells and the release of mediators such as tryptase and 
cytokines which regulate the ASM cell function and induce goblet cell hyperplasia 
(Okayama et al., 2007). Moreover, eosinophils produce basic proteins such as 
ECP and MBP which damage the epithelium of the airway, subsequently leading 
to AHR (Wills-Karp, 1999). 
Besides inflammation, airway remodeling, generally described as structural 
changes in the airway such as epithelial metaplasia, airway fibrosis, and ASM 
hyperplasia, also contribute to AHR (Fixman et al., 2007). Both inflammatory 
cells and structural cells, such as epithelial cells, ASM cells, and fibroblasts, take 
part in the regulation of airway remodeling and AHR (Leigh et al., 2004). 
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Abundant data has shown that both the hyperplasia of ASM and enhanced 
deposition of extracellular matrix (ECM) are apparent in both asthmatic patients 
and animal models (Fixman et al., 2007; Woodruff et al., 2004). Quick reaction to 
inhaled allergens and rapid turnover rate of epithelium are also features of asthma. 
Furthermore, airway epithelium participates in airway remodeling by producting 
epithelial cell-specific growth factors and regulating goblet cell differentiation 
(Fixman et al., 2007). In addition, in asthmatic models with specific deletion of 
IKKβ in the epithelium, mice exhibited reduced mucus production, fibrosis, and 
airway thicking, suggesting NF-κB signaling pathways play a pivotal role in 
airway epithelium induced airway remodeling (Broide et al., 2005). Consistent 
with previous studies, recently, it has been shown that selective activation of NF-
κB in the airway epithelium is sufficient to provoke AHR and cause the thickening 
of ASM (Pantano et al., 2008). 
AHR, as a constant feature of the asthma, is the result of a combination of 
various mechanisms. Multiple measures should be done to reduce this prevalent 
and common phenotype in asthma patients. 
1.1.4.    Current therapy for asthma 
Current therapy for asthma comprises of bronchodilators and anti-
inflammatory agents. A combination of inhaled corticosteroids and short-acting or 
long-acting β2-adrenoceptor agonists is the first line therapy for the control of 
mild to severe asthma patients (Holgate and Polosa, 2008). Although most of the 
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asthmatics can be controlled by current therapy, up to 15% patients do not respond 
well to current therapy and suffer from uncontrollable symptoms (Amon et al., 
2006). There is a demand to develop new drugs for asthma patients.   
Inhaled corticosteroids (CS) are the most effective drugs for both the control 
of symptoms and improvement of lung function in asthma patients (Barnes, 2006). 
CS is able to quickly cross cell membranes and bind to glucocorticoid receptors 
(GR) (Rhen and Cidlowski, 2005). Following ligand binding, GR dimer 
translocates into the nucleus where CS regulates the transcriptional activity of 
target genes by different mechanisms including gene transactivation and gene 
transrepression, leading to the inhibition of expression of cytokines, chemokines 
and adhesion molecules (Goulding, 2004; Holgate and Polosa, 2008; Rhen and 
Cidlowski, 2005). Although CS targets a variety of inflammatory mechanisms and 
is highly effective for the control of asthma, 10 to 15% of patients are insensitive, 
even to high doses of oral corticosteroids. Some severe asthma patients need oral 
steroid as a regular treatment. Furthermore, there has been increasing concerns 
about the systemic and local side effects of CS. Reasonable add-on therapies may 
give greater benefits for asthmatic patients than increasing the dose of CS.  
Selective β2 adrenergic agonists, the most important bronchodilator in asthma 
treatment, include short-acting (e.g. salbutamol and levalbuterol) and long-acting 
(e.g. salmeterol and formoterol) compounds (Amon et al., 2006). They act on β2 
adrenergic receptors and result in the formation of cyclic adenosine 
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monophosphate through activation of G proteins, causing relaxation of smooth 
muscles of airways. However, recently, there are more and more studies 
suggesting that regular treatment with long-acting β2 adrenergic agonists could 
increase both exacerbation and death rates of asthma patients (Martinez, 2005; 
Salpeter et al., 2006). Although mechanisms regarding the deterioration of asthma 
symptoms through the  usage of β2 adrenergic agonists remain unclear, asthma 
guidelines have suggested that long-acting β2 adrenergic agonists should be given 
in combination with CS (Kelly, 2007).  
Leukotrienes, including cysteinyl LTs (LTC4, LTD4, and LTE4) and LTB4, 
are arachidonic acid derivatives formed by 5-lipoxygenase and 5-lipoxygenase-
activating protein (Peters-Golden and Henderson, 2007). Cysteinyl LTs are the 
most potent endogenous bronchoconstrictors and play an important role in 
asthmatic inflammation. LTB4 is a potent chemoattractant for neutrophils, but has 
little effect on bronchoconstriction. Commonly used cysteinyl LT antagonists 
consist of montelukast and zafirlukast, which block cysteinyl LT1 receptor 
binding sites, thereby improving asthmatic symptoms. Furthermore, zileuton, a 5-
lipoxygenase inhibitor, blocks endogenous production of both cysteinyl LTs and 
LTB4. It has been well documented that LT antagonists could clinically alleviate 
asthma symptoms and reduce the dose of CS in both adults and children (Dahlen, 
2006). 
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IgE which recognizes allergens, is associated with the AHR and local 
inflammation in asthma. Omalizumab (Xolair), a recombinant DNA-derived 
humanized IgG1κ monoclonal antibody against IgE, was approved by the U.S. 
Food and Drug administration for the treatment of severe or refractory asthma 
patients in June 2003 (Avila, 2007). However, there are still lots of concerns about 
the side effects of omalizumab. There is insufficient information on the long-term 
effectiveness and side effects of this drug. Although the IgE pathway is not an 
important mechanism with which the immune system fights against the 
development of cancers, there was a small increase in the incidence of 
malignancies in omalizumab-treated groups compared with placebo-treated groups 
(Avila, 2007). The neoplasias caused by omalizumab are still being evaluated in 
Phase Ⅳ studies.    
Theophylline is a moderately potent bronchodilator and has both 
immunomodulatory and anti-inflammatory actions at low concentration. 
Traditionally, the therapeutic effects of theophylline have been attributed to its 
nonselective phosphodiesterase inhibition, but there might be other mechanisms 
for this drug. The major limitation of theophylline is its narrow therapeutic index. 
Therefore, theophylline is now considered as the second-line therapy for asthma 
(Boswell-Smith et al., 2006).    
1.1.5.    New therapy for asthma 
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With an improved understanding of the pathophysiology of asthma, a variety 
of new approaches and new targets have been investigated in the last decade, 
providing insights for asthma therapies (Amon et al., 2006; Tarantini et al., 2007).  
Th2 cytokines (e.g. IL-4, IL-5, and IL-13) are important in the development of 
asthma and are promising targets for the treatment. Efficacy of soluble IL-4 
receptor (sIL-4R) has been investigated in two studies, both of which indicated 
sIL-R improves both lung function and asthma symptoms in patients (O'Byrne, 
2006). However, there are no published reports confirming these results in larger 
scale trials.  Anti-IL-5 humanized monoclonal antibodies (e.g. mepolizumab and 
SCH 557700) have been shown to decrease both blood and sputum eosinophils, 
but could not improve patient`s symptoms dramatically (O'Byrne, 2006).  
TNF-α has been implicated in airway inflammation, AHR, and airway 
remodeling in asthma patients, especially severe refractory patients (Berry et al., 
2006). Several TNF-α blockers, such as infliximab (a chimeric mouse/humanized 
mAb), etanercept (a soluble fusion protein combining 2p75 TNF receptors with an 
Fc fragment of human IgG1), and adalimumab (a fully human mAb) have been 
tested in clinical trials (Brightling et al., 2007). However, preliminary data from 
clinical trials are controversial. It is likely that TNF-α blockers would only work 
in a small group of severe refractory asthma patients. Heterogeneity in response to 
TNF-α blockers in asthma patients should be considered for future studies. 
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Phosphodiesterase type 4 (PDE4) is a group of enzymes encoded by at least 
four distinct genes (PDEA, PDEB, PDEC, PDED), which hydrolyze cAMP into 5-
monophosphates, an inactive form (Fan Chung, 2006). PDE4 inhibitors act by 
increasing intracellular cAMP and have been shown to exert a wide range of anti-
inflammatory effects (Boswell-Smith et al., 2006; Fan Chung, 2006). Several 
PDE4 inhibitors have been developed for the treatment of both asthma and COPD, 
but only Roflumilast (Altana) and Cilomilast (GlaxoSmithKline) have proceed to 
phase ΙΙΙ clinical trials (Lipworth, 2005). There are doubts about the therapeutic 
values of PDE4 inhibitors and concerns about their side effects, particularly 
nausea and vomiting. 
Protein kinases are a group of enzymes which add the γ phosphate of ATP or 
GTP to tyrosine, serine, and threonine residues of target proteins. Because kinases 
are critical in the amplification of inflammatory signals in the pathogenesis of 
asthma, several kinase inhibitors have been developed to reduce the allergic 
responses (Adcock et al., 2006). MAPK kinase inhibitor (U0126), p38 MAPK 
inhibitors (SB239063 and respirable p38alpha MAPK antisense oligonucleotide) 
and c-Jun NH2-terminal kinase (JNK) inhibitor (SP600125) have been shown to 
be able to attenuate allergic inflammation in asthmatic models (Duan and Wong, 
2006). IKKβ inhibitors are associated with reduced airway inflammation and AHR 
in mouse model (Ziegelbauer et al., 2005). In addition, some tyrosine kinase 
inhibitors, such as Syk inhibitor (BAY 61-3606), Lyn inhibitor (Lyn-binding 
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peptide), and JAK3 inhibitor (CP-690550) are effective in asthmatic models 
(Kudlacz et al., 2008; Wong, 2005). Kinase inhibitors, especially those aiming at 
MAPK and NF-κB pathways, are promising as an accurate bullet targeting 
inflammatory cascades; however, specificity, efficacy, and possible side effects 
should be kept in mind, as these inhibitors proceed to clinical trials (Bain et al., 
2003; Park and Christman, 2006).    
1.2. NF-κB signaling pathway 
1.2.1. Introduction of the NF-κB pathway 
The nuclear factor-κB (NF-κB)/REL (v-rel reticuloendotheliosis viral 
oncogene homolog) family is a central player in coordinating both innate and 
adaptive immunity. Approximately 20 years ago, three proteins (NF-κB, v-Rel, 
and Dorsal) were coincidently discovered and soon demonstrated to be different 
members of the same NF-κB family (Sen and Baltimore, 1986; Singh et al., 1986). 
Today, with an exponential increase in information regarding NF-κB pathways, it 
is now considered a ubiquitous pathway involved in the regulation of a broad 
array of genes in response to diverse stimuli (Perkins, 2007).   
The NF-κB/REL transcription factor family consists of two subfamilies: the 
NF-κB proteins and the Rel proteins (Figure 1.3) (Gilmore, 2006; Perkins, 2007). 
All of these proteins share a structurally conserved DNA-binding/dimerization 
domain, known as Rel homology domain (RHD), and have functions conserved 



















Figure 1.3 Members of NF-κB family (Adapted from Perkins, 2007). Definition of 
abbreviations: ANK = ankyrin-repeat motifs; DD = death domain; RHD = Rel 












The NF-κB proteins, including p105 and p100, contain long C-terminal domains 
with several ankyrin repeats which auto-inhibit these proteins. Upon either limited 
proteolysis or arrested translation, NF-κB become shorter proteins (p105 to p50 
and p100 to p52), which are the main DNA-binding units when they form dimers 
with other Rel proteins. The Rel proteins including c-Rel, RelB, and RelA (p65), 
contain C-terminal transactivation domains which activate transcription of genes 
in dimeric forms. Furthermore, the p50/p65 heterodimer, the most common 
activated form of NF-κB transcription factor, is ubiquitous in all cell types; p52 is 
expressed in epithelium, macrophages, lymphocytes, and dendritic cells; RelB is 
restricted to dendritic cells and lymphocytes; c-Rel is confined to haematopoietic 
cells (Bottero et al., 2006). The specific expression of NF-κB proteins in 
particular cell types implies their distinct functions in immune system. 
Besides NF-κB family, there are also two other important groups of proteins 
(IκB family and IKK complex) which are involved in the regulation of NF-κB 
pathways. There are three principal IκBs (IκBα, IκBβ, and IκBε) which retain NF-
κB dimers in the cytoplasm, in part by masking a conserved nuclear localization 
sequence in the RHD of NF-κB subunits (Li and Verma, 2002). IKK complex 
comprises of three main subunits: the catalytic subunits IKKα and IKKβ (also 
called IKK1 and IKK2 repectively), and the regulatory subunit IKKγ (also called 
NF-κB essential modifier [NEMO]) (Hacker and Karin, 2006; Scheidereit, 2006). 
IKKβ and NEMO are the predominant components in IKK complex in the 
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canonical pathway, whereas IKKα appears to stimulate p100 precursor processing 
and regulates NF-κB-independent developmental processes (Bonizzi and Karin, 
2004; Scheidereit, 2006). Various genetic experiments in mice have been done to 
investigate the functions of NF-κB, IκB, and IKK in physiological processes and 
human diseases (Table 1.2) (Gerondakis et al., 2006; Pasparakis et al., 2006). In 
most quiescent cells, NF-κB forms an inactive complex with its inhibitor, IκBα, in 
the cytoplasm. Upon various stimuli, such as pro-inflammatory cytokines (TNF-α 
and IL-1), lipopolysaccharides (LPS), engagement of TCR, viruses (rhinovirus 
and adenovirus), oxidative stress (O3, H2O2 and NO2), and ultraviolet light, NF-
κB pathways will be activated predominantly through canonical and non-
canonical pathways (Figure 1.4) (Perkins, 2007). In the canonical pathway, 
numerous NF-κB stimuli, such as TNF-α, antigen, LPS, can activate the IKK 
complex. The regulatory subunit NEMO is essential to the activation of IKK 
complex. In response to stimuli, NEMO is ubiquitylated at Lys63 and subsequently 
recruits some kinases such as transforming growth factorβ activated kinase-1, 
which phosphorylate IKKβ at Ser177/181, leading to the activation of IKK complex. 
IκBα is phosphorylated by the activated IKK complex at Ser32 and Ser36. Then, 
phosphorylated IκBα is ubiquitinylated at Lys21 and Lys22 by β-transducin repeat-







Table 1.2 Knockout mouse models for the NF-κB pathway (Adapted from 
Gerondakis et al., 2006). 
 
Mutated Gene Phenotype in knockout mice References 
RelA (P65) Die at E15 to E16; TNF-α mediated fetal 
hepatocyte apoptosis 
(Beg et al., 
1995b) 
RelB Multiple organ inflammations and 
hematopoietic abnormalities 
(Burkly et al., 
1995); 
c-Rel Defects in lymphocyte and macrophage 
functions 








Defects in lymphoid organ development (Franzoso et al., 
1998) 
IκBα Die postnatally due to immune deficiency; 
constitutive NF-κB acitivity 
(Beg et al., 
1995a) 
IκBε Increased expression of certain Ig isotypes 
and cytokines 
(Memet et al., 
1999) 
IKKα (IKK1) Die at birth; Skeletal and epidermal defects (Hu et al., 
1999) 
IKKβ (IKK2) Die at E13 due to TNF-α dependent liver 
apoptosis 
(Li et al., 1999) 



































After that, NF-κB dimer is released from the cytoplasmic NF-κB-IκB complex 
and translocates to the nucleus. In the nucleus, the NF-κB dimer binds to a 9-10 
base pair DNA site, known as κB sites (5’-GGGPuNPyPyPyCC-3’, where Pu = 
purine, N = any nucleic acid, Py = pyrimidine), leading to the transcription of a 
variety of downstream genes. These genes comprise of cytokines (TNF-α, IL-1β, 
IL-5, IL-6, IL-13 and GM-CSF), chemokines (IL-8, eotaxin, RANTES, and 
monocyte chemoattractant protein-1 [MCP-1]), adhesion molecules (ICAM-1, 
VCAM-1, and E-selectin), and enzymes (COX-2 and iNOS) (Bonizzi and Karin, 
2004). In the non-canonical pathway, the p100-RelB dimer is activated by 
phosphorylation of the C-terminal region of p100 by the IKKα homodimer. Then, 
the proteasome-dependent processing of p100 to p52 causes the activation and 
translocation of p52-RelB heterodimers. After that, the binding of p52-RelB to 
distinct κB sites in the nucleus results in the expression of genes mainly involved 
in the development and maintenance of secondary lymphoid organs (Bonizzi and 
Karin, 2004). However, recent studies have suggested that the regulation of NF-
κB pathways is more complicated than that defined by the canonical and non-
canonical pathways. For instance, there are many post-translational modifications 
for NF-κB subunits. RelA is phosphorylated by protein kinase A at Ser276, by 
glycogen synthase kinase-3β (GSK-3β) at Ser468 and Ser536, and by IKKβ at Ser536 
(Mattioli et al., 2004; Perkins, 2007; Yang et al., 2003). Moreover, the 
transcriptional activity of RelA is regulated by both coactivators, such as p300 and 
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CREB binding protein (CBP), and corepressors such as histone deacetylase 
(HDAC)s (Li and Verma, 2002). Furthermore, there are crosstalks between NF-κB 
pathways and other signaling pathways including JNK, p53, and various nuclear 
receptors (Perkins, 2007).  
NF-κB pathways play a central role in both biological functions and human 
diseases. Genetic studies have unequivocally revealed a pivotal role of NF-κB in 
the differentiation and maturation of hematopoietic cells and lymphoid 
organogenesis (Figure1.5) (Bottero et al., 2006). Due to the rapid turnover rate of 
hematopoietic cells, the immune system including all lymphoid and myeloid 
lineages, is heavily influenced by NF-κB pathways. Aberrant activation of NF-κB 
pathways have been linked to a variety of diseases such as inflammation, cancer, 
arthritis, atherogenesis, asthma, etc (Kumar et al., 2004). However, further studies 
have revealed more complicated roles for NF-κB pathways (Greten et al., 2007; 
Perkins and Gilmore, 2006). NF-κB pathways can exhibit opposing behaviors in 
the same biological process. For instance, NF-κB promotes cancer pathogenesis 
through induction of anti-apoptotic genes and proinflammatory genes, whereas 
NF-κB can also suppress tumor activity by induction of p53-induced apoptosis 
and pro-apoptotic genes (Perkins and Gilmore, 2006). It has been shown that the 
inhibition of IKKβ could increase the secretion of IL-1β in an endotoxin-induced 
sepsis mouse model, via a caspase dependent manner, suggesting potential 















Figure 1.5 The functions of NF-κB in hematopoietic differentiation (Adapted from 









Further studies in this area are required for better understanding the complex 
mechanisms of NF-κB activity and related diseases. 
1.2.2.  Role of the NF-κB pathway in allergic inflammation 
Cumulative evidence has suggested that the NF-κB signaling cascade plays 
a pivotal role in the initiation and development of asthma in both allergic animal 
models and human asthma patients (Kumar et al., 2004; Poynter et al., 2002). 
Persistent NF-κB DNA-binding activity was detected in both bronchial biopsies 
and induced sputum of asthmatics. In addition increased levels of p65 were found 
in airway epithelial cells from bronchial biopsies of asthmatics (Hart et al., 1998). 
High levels of phosphorylated IκBα, IKKβ, p65, and NF-κB DNA-binding 
activity were detected in peripheral blood mononuclear cells (PBMC) of severe 
asthmatics compared to normal subjects (Gagliardo et al., 2003). Moreover, these 
PBMC produced high levels of IL-8, RANTES, and GM-CSF, which were 
inhibited by the NF-κB inhibitor (Gagliardo et al., 2003). House dust allergen Der 
p1, a common trigger of bronchial asthma, promotes NF-κB activation in the 
asthmatic bronchial epithelial cells (Stacey et al., 1997). Furthermore, a broad 
array of genes involved in pathogenesis of asthma, such as IL-9, IL-13, eotaxin, 
TSLP, ICAM-1, VCAM-1, E-selectin, etc, contain κB sites within their promoters, 
supporting the role of NF-κB in the allergic inflammation (Ahn and Aggarwal, 
2005). NF-κB also promotes the transcription of genes that are involved in airway 
remodeling and mucus hypersecretion in the bronchial epithelium (Broide et al., 
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2005). Several NF-κB knockout asthma mouse models have shown reduced 
airway inflammations following the challenge by allergens (Donovan et al., 1999; 
Poynter et al., 2004; Yang et al., 1998). Moreover, corticosteroids, the most 
effective drug for the control of asthma, are also a potent inhibitor of NF-κB 
pathways in mice and cultured cells (Auphan et al., 1995). In addition to 
corticosteroids, numerous other NF-κB inhibitors, such as NF-κB-specific decoy 
oligonucleotide, p65-specific antisense oligonucleotide, and IKKβ selective small 
molecule inhibitors have demonstrated beneficial effects in experimental asthma 
models (Birrell et al., 2005; Choi et al., 2004; Desmet et al., 2004; Ziegelbauer et 
al., 2005). Collectively, these findings suggest that the constitutive activation of 
NF-κB pathways is one of the primary effectors in the pathogenesis of asthma and 
pharmacological agents targeting the NF-κB cascade may be promising in the 
treatment of asthma. 
1.3. Inhibitors of NF-κB signaling cascades  
NF-κB plays a pivotal role in both physiological and pathological processes, 
regulating immune responses, the development of cells, and even the expression 
of some anti-viral genes. Thus, a variety of therapeutic approaches targeting the 
NF-κB pathway have been developed, especially for chronic inflammation and 
cancer where this pathway is often constitutively active (Ahn et al., 2007; 
D'Acquisto et al., 2002). With an increasing understanding of the NF-κB pathway, 
more than 700 inhibitors, aimed at different levels of this pathway, have been 
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identified (Gilmore and Herscovitch, 2006). These compounds comprise of 
peptides, small RNA/DNA, natural medicinal herbs, and small synthetic 
molecules. However, until now, no compounds, designed as a specific NF-κB 
inhibitor, have been approved clinically, indicating that more work needs to been 
done in developing potent NF-κB inhibitors with minimal side effects (Uwe, 
2008). 
1.3.1. The GSK-3β inhibitor 
1.3.1.1.   The GSK-3 pathway 
Glycogen synthase kinase-3 (GSK-3) is a serine-threonine kinase that exists in 
two isoforms in mammalian cells, namely GSK-3α and GSK-3β (Woodgett, 1990). 
Although it was originally discovered based on its ability to phosphorylate and 
inactivate glycogen synthase, GSK-3 was found to play a key role in regulating 
the functions of a wide array of  substrates including metabolic and signaling 
proteins, structural proteins, and more importantly transcription factors (Embi et 
al., 1980; Jope and Johnson, 2004; Rylatt et al., 1980).  
One of the best studied functions of GSK-3 is its role in the wingless and int-1 
(WNT) signaling pathway. A proportion of GSK-3 forms a stable complex with 
axin, the adenomatous polyposis coli protein, and β-catenin in cells, leading to the 
phosphorylation of β-catenin and subsequent ubiquitination and proteolytic 
degradation. Upon binding of WNTs to its receptors, GSK-3 is inhibited by FRAT 
(frequently rearranged in advanced T-cell lymphomas) and dissociates from the 
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complex. Then, the dephosphorylated β-catenin translocates into the nucleus, 
binds to the T-cell factor transcription factor, and stimulates the expression of 
embryogenesis related genes (Cohen and Frame, 2001). 
GSK-3 activity can be regulated by phosphorylation, localization, and 
interaction with GSK-3 binding proteins. Among these mechanisms, 
phosphorylation is the most studied one. GSK-3 activity is greatly inhibited 
following phosphorylation at a serine residue near its N-terminal (Ser21 in GSK-3α 
or Ser9 in GSK-3β). In contrast, GSK activity is enhanced by phosphorylation of 
Tyr279 in GSK-3α or Tyr216 in GSK-3β (Jope and Johnson, 2004). The activity of 
GSK-3 is also regulated by its substrate. GSK-3 is a unique protein kinase in that 
some of its substrates need to be first phosphorylated by another protein kinase at 
a serine or threonine residue, known as priming phosphate, which is located four 
residues carboxy-terminal to the site of GSK-3 phosphorylation (ter Haar et al., 
2001). In active state, the substrate with a priming phosphate binds to a pocket in 
GSK-3 which contain three crucial basic residues (Arg96, Arg180, and Lys205), 
aligning it in a position that GSK-3 can phosphorylate a serine or threonine four 
residues to the priming phosphate and activate the substrate (Cohen and Frame, 
2001; Dajani et al., 2001).  
1.3.1.2.    GSK-3β and the NF-κB pathway 
Cumulative evidence indicates that GSK-3 is necessary for the full 
transcriptional activity of NF-κB pathway (Dugo et al., 2007; Jope et al., 2007). In 
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year 2000, Hoeflich and collegues showed that GSK-3β knockout mice resulted in 
embryonic lethality and displayed a phenotype consistent with p65- and IKKβ-
deficient mice (Hoeflich et al., 2000). In addition, GSK-3β is necessary for the 
NF-κB mediated anti-apoptotic response to TNF-α and the role of GSK-3β in this 
biologic process could not be compensated for by GSK-3α (Hoeflich et al., 2000). 
Followed by this discovery of the role of GSK-3β in the regulation of NF-κB 
pathway, a series of studies using GSK-3β inhibition reveals that GSK-3β can 
positively regulate the activity of NF-κB pathway (Dugo et al., 2005; Dugo et al., 
2007; Martin et al., 2005; Whittle et al., 2006). It has been shown that inhibition 
of GSK-3 could  suppress transcription of the NF-κB-dependent inducible nitric 
oxide synthase gene, and the inhibition of GSK-3 protects hepatocytes from TNF-
α induced apoptosis through the phosphorylation of p65 (Schwabe and Brenner, 
2002). It was reported that NF-κB activation upon stimulation by LPS, IL-1β, or 
cigarette smoke condensate was entirely inhibited in GSK-3β(-/-) cells (Takada et 
al., 2004). In addition, GSK-3β is necessary for the efficient translocation of p65 
into nucleus and binding to the promoter regions of IL-6 and MCP-1 upon 
stimulation by TNF-α (Steinbrecher et al., 2005). It has been postulated that in 
response to TNF-α stimulation, GSK-3β facilitates the phosphorylation of NF-κB 
subunit p105, leading to the formation of NF-κB subunit p50 (Demarchi et al., 
2003). Interestingly, several groups have reported that a high level of β-catenin 
following the inhibition of GSK-3β could reduce the activity the NF-κB through 
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certain unidentified mechanisms (Deng et al., 2002; Deng et al., 2004; Duan et al., 
2007). Taken together, GSK-3β has been shown to positively regulate the activity 
of NF-κB pathway, albeit the fact that the exact mechanisms remain to be 
elucidated.  
1.3.1.3.    GSK-3β inhibitors 
Due to the crucial role of GSK-3β in the pathophysiology of inflammatory 
disorders, there are a variety of GSK-3β inhibitors that have been tested as 
therapeutics for diabetes, Alzheimer`s disease, and inflammatory diseases (Meijer 
et al., 2004). Lithium, a popular drug for the bipolar disorder, is the best-
characterized GSK-3 inhibitor and widely used as a pharmacological tool to 
investigate the role of this kinase in biological processes (Jope, 2003). However, 
lithium also affects other kinases and its Ki value (mM) is relatively high 
compared with other specific inhibitors (Bain et al., 2003; Doble and Woodgett, 
2003). Insulin, an endogenous GSK-3 inhibitor, may also exert its beneficial 
effects in the treatment of sepsis by reducing the activity of GSK-3β (Dugo et al., 
2006; Eldar-Finkelman et al., 1999). Besides, a panel of adenosine triphosphate 
(ATP)-competitive GSK-3 inhibitors, such as SB415286, beryllium, and 
hymenialdisine, has been identified by screening chemical databases (Doble and 
Woodgett, 2003). However, because there is only a single amino acid difference in 
the ATP-binding site of GSK-3 (Glu196 in GSK-3α, Asp133 in GSK-3β), these 
inhibitors are unable to distinguish between the two isoforms of GSK-3 (Meijer et 
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al., 2004). Since ATP-binding sites among all kinases are similar to some extent, 
these ATP-competitive GSK-3 inhibitors could affect other protein kinases. In 
addition this ATP-competitive inhibition is easily reversed by a high concentration 
of ATP, a constitutive component of cells. 
In year of 2002, Martinez and colleagues described the first non-ATP-
competitive GSK-3β inhibitor, known as 4-benzyl-2-methyl-1,2,4-thiadiazolidine-
3,5-dione  (TDZD-8) (Figure 1.6) (Martinez et al., 2002). TDZD-8 was shown to 
be a potent GSK-3β inhibitor (IC50 = 2 µM) and exhibited low specificity (IC50 > 
100 µM) for cyclin-dependent kinases, enzymes structurally similar to GSK-3β. In 
addition, TDZD-8 did not show inhibitory effects on other kinases such as protein 
kinase A (PKA), protein kinase C (PKC), and casein kinase II (CK-II). The 
possible binding mode of TDZD-8 and GSK-3β was proposed based on the 3D 
crystalline structure of GSK-3β (Figure 1.7) (Martinez et al., 2005; Martinez et al., 
2002). The superior potency and selectivity makes TDZD-8 ideal for studying 
potential anti-inflammatory effects in a mouse asthma model through inhibition of 








































Figure 1.7 Proposed binding mode of TDZD-8 to GSK-3β (Adapted from 














1.3.2.1.    Introduction of andrographolide 
Andrographis paniculata Nees (Family, Acanthaceae), also called the king of 
bitters due to its bitterness, is widely cultivated in southern Asia including China, 
India, Malaysia, Indonesia, Sri Lanka, etc (Figure 1.8) (Negi et al., 2007). This 
plant is known by various vernacular names such as Chuan Xin Lian in China, 
Kalmegh and Bhunimba in India, and Hempedubumi in Maylaysia. In addition, 
andrographis paniculata has been used as a herbal medicine for a long time in Asia 
and Scandinavia. The leaves and stems of this plant are used to extract the active 
phytochemicals. The active components of andrographis paniculata include 
andrographolide, neoandrographolide, andrographoside, and neoandrographoside 
(Figure 1.9). Although each component possesses distinct features in terms of 
pharmacological activity, andrographolide is the most active and documented 
component in this plant. Andrographolide is present in all parts of andrographis 
paniculata, especially in the leaves (around 2%) (Negi et al., 2007). Chemically, 
andrographolide is named as 3-[2-[decahydro-6-hydroxy-5-(hydroxymethyl)-5,8α-
dimethyl-2-methylene-1- napthalenyl]ethylidene]dihydro-4-hydroxy-2(3H)-
furanone, and its structure and stereochemistry have been intensively studied 
(Chakravarti and Chakravarti, 1951; Pramanick et al., 2006). Andrographolide is 















































1.3.2.2. Andrographolide and the NF-κB pathway 
Andrographolide has shown a wide range of therapeutic effects such as anti-
viral (Calabrese et al., 2000), anti-thrombotic (Thisoda et al., 2006; Zhao and 
Fang, 1991), anti-cancer (Jiang et al., 2007; Liang et al., 2008; Rajagopal et al., 
2003; Sheeja and Kuttan, 2007a; Zhao et al., 2008), hepatoprotective (Jain et al., 
2000; Singha et al., 2007; Visen et al., 1993), and modulation of immune 
responses (Sheeja and Kuttan, 2007b; Xu et al., 2007). More recently, it has been 
suggested that andrographolide also has anti-inflammatory activities. 
Andrographolide was thought to suppress the migration of inflammatory cells by 
reducing the expression of adhesion molecules (Wang et al., 2007). In addition, in 
RAW cells, upon stimulation by LPS and IFNγ, protein level and enzyme activity 
of inducible nitric oxide synthase (iNOS) were reduced following treatment with 
andrographolide (Chiou et al., 2000). Furthermore, andrographolide reduces LPS 
induced microglia damage by inhibiting proinflammatory cytokines such as iNOS 
and COX-2 (Wang et al., 2004) and suppresses the production of both TNF-α and 
IL-12 in LPS stimulated murine peritoneal macrophages (Qin et al., 2006). 
Although the anti-inflammatory effects of andrographolide is well established, 
little is known about the exact mechanisms of this compound and various 
hypotheses have been proposed. One convincing observation of the anti-
inflammatory activity of andrographolide is via the inhibition of NF-κB pathways 
reported by Xia and coworkers (2004). They showed that andrographolide could 
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bind to reduced cys62 of p50, inhibiting the formation of p50/p65 hererodimer and 
NF-κB transcriptional activity (Xia et al., 2004). Inhibitory effects of 
andrographolide on NF-κB activity is further supported by experiments on an 
arterial injury model (Wang et al., 2007) and neutrophilic cells (Hidalgo et al., 
2005). Furthermore, andrographolide has been found to suppress the expression of 
various molecules such as iNOS, COX-2, E-selectin, VCAM-1, etc, which are all 
regulated by NF-κB based pathways (Kumar et al., 2004). Therefore, it is essential 
to find out if andrographolide would exert anti-inflammatory effects in a mouse 
asthma model and to explore underlying anti-inflammatory mechanisms. 
1.4. The animal model of asthma 
Experimental models of asthma have contributed greatly to the understanding 
of the pathogenesis of asthma and the development of new therapies for past 
decades (Zosky and Sly, 2007). Many species of animals are commonly used as 
models to investigate asthma, including mice, rats, guinea pigs, monkeys, ferrets, 
cats, dogs, pigs, and horses (Kurucz and Szelenyi, 2006). Generally, every species 
has its pros and cons, and species-specific differences include anatomical 
properties, and physiological and immunological responses (Zosky and Sly, 2007).   
Among these asthmatic models, mouse models of asthma are, undoubtedly, 
the most popular choice for asthma studies (Zosky and Sly, 2007). The mouse 
model mimics many features of human asthma. After sensitization and challenge 
with antigens, mouse asthmatic models display a classical Th2 type immunologic 
 53 
response with lung eosinophilia, high antigen-specific IgE and IgG, mucus 
hypersecretion, and AHR (Zosky and Sly, 2007). Furthermore, due to the 
availability of wild-type, mutant, knockout and transgenic mice, it is easy to 
investigate functions of a specific gene in the initiation and development of 
asthma in the mouse model. In addition, there are a wide variety of immunological 
reagents available for the study of mouse species. Finally, studies on mouse 
asthmatic models have highlighted the importance of Th2 cytokines such as IL-4, 
IL-5, and IL-13, in allergic responses. Therefore, we chose the mouse asthmatic 
model to investigate the anti-inflammatory effects of TDZD-8 and 
andrographolide in relation to NF-κB signaling pathways. 
We used a typical sensitization and challenge protocol with female BALB/c 
mouse.  BALB/c mouse is a high-responder mouse strain in which both airway 
inflammation and AHR are easily induced. The immune system shows a marked 
gender differences, for instance women are more susceptible to autoimmune and 
inflammatory diseases (Da Silva, 1999). Female mice displayed a higher serum 
IgE level and are more susceptible to airway inflammation than male mice 
(Corteling and Trifilieff, 2004; Hayashi et al., 2003; Melgert et al., 2005).  We 
used OVA as the antigen for asthma model, because it has been produced via the 
standardized protocol by the industry and is easily manipulated to avoid the 
exposure to mouse immune system before sensitization. Aluminium hydroxide 
 54 
was used as the adjuvant to promote the Th2 responses of the immune system in 
the mouse asthma model (Brewer et al., 1999).  
However, no animal model could completely mimic asthma in humans and 
each model has its limitations and advantages (Epstein, 2004). For instance, the 
mouse model lacks the chronic inflammatory response to long-term challenge with 
antigens. Moreover, immunological responses in mouse asthmatic models are even 
being suppressed by long-term challenge following sensitization due to immune 
tolerance (Epstein, 2004). Therefore, we should keep these limitations in mind 



































Asthma is a chronic airway disease which affects around 300 million people 
of all ages and ethnic backgrounds (Masoli et al., 2004). The pathophysiology of 
asthma is multifactorial, involving an intricate network of molecular and cellular 
interactions.  Besides, both genetic background and environmental factors also 
contribute to the initiation and development of asthma (Busse and Lemanske, 
2001).  
Current therapies for asthma mainly rely on β2 agonists and inhaled 
corticosteroids. While inhaled corticosteroids are at present the most effective 
anti-inflammatory agents for asthma, major concerns about the systemic effects of 
inhaled corticosteroids remain. Furthermore, up to 15% of patients who suffer 
from uncontrollable asthmatic symptoms do not respond well to corticosteroids 
(Amon et al., 2006). There is an urgent need to discover and develop novel and 
potent anti-inflammatory drugs for asthma. 
Advances in the understanding of the pathophysiology of asthma have shed 
light on the development of novel therapies for asthma. The NF-κB family plays a 
key role in the initiation and development of asthma (Kumar et al., 2004). 
Therefore, the development of specific inhibitors targeting the NF-κB signaling 
pathway is promising for attenuating allergic responses. Nevertheless, because the 
NF-κB transcription factors are central to both normal biological functions and 
pathological conditions, direct inhibition of NF-κB per se may not be a safe 
approach. Rather, appropriate and specific inhibition of signaling molecules that 
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regulate NF-κB may be an effective anti-inflammatory strategy for asthma (Uwe, 
2008).  
GSK-3β has been known to regulate the phosphorylation of p65 in the NF-κB 
pathway and andrographolide has been shown to interfere with the activity of NF-
κB pathway. The objectives of my thesis project were to examine the potential 
anti-inflammatory effects of a GSK-3β inhibitor, TDZD-8 (Martinez et al., 2002) 
and a herbal medicinal, andrographolide (Negi et al., 2007)) in a mouse asthma 
model and elucidate their mechanisms in the regulation of NF-κB pathway. In the 
future, the aims are to develop efficacious therapies that are easy to comply with 



























3.1. Materials and reagents 
Drugs and chemicals used in this PhD project are as follows: 3-[2-[decahydro-6-
hydroxy-5-(hydroxymethyl)-5,8α-dimethyl-2-methylene-1- 
napthalenyl]ethylidene]dihydro-4-hydroxy-2(3H)-furanone (andrographolide) , anti-β-
actin monoclonal antibody, 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione 
(TDZD-8), 10% neutral buffered formalin, acetyl-β-methylcholine chloride, 
aluminium hydroxide (Al(OH)3), bovine serum albumin (BSA), chicken ovalbumin 
(OVA), dimethyl sulfoxide (DMSO), eosin Y, Harris hematoxylin solution, 
hematoxylin solution Gill no. 3, heparin, periodic acid solution, Schiff’s reagent, and 
Tween 20 (Sigma-Aldrich, St Louis, MO, USA); RNAlater (Applied Biosystems, 
Foster City, CA, USA); alkaline phosphatase (AP) conjugate substrate kit, agarose, 
blotting paper, polyvinylidene difluoride (PVDF) membrane, 
tetramethylethylenediamine (TEMED), 3,3´,5,5´-tetramethylbenzidine (TMB) 
substrate kit, Triton X-100 (Bio-Rad Laboratories, Hercules, CA, USA) ammonium 
chloride (NH4Cl) (BDH Laboratory Supplies, Poole, England); agarose, phosphate 
buffered saline (PBS), sodium dodecyl sulfate (SDS), and tris-acetate-EDTA (TAE) 
(1st BASE, Singapore); diethylpyrocarbonate (DEPC)-treated water, 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer, penicillin, L-
glutamine, streptomycin, random primer, Roswell Park Memorial Institute (RPMI) 
medium, Trizol, and trypan blue (Invitrogen, Carlsbad, CA, USA); anti-mouse IL-13 
monoclonal antibody, biotinylated anti-mouse IL-13 antibody, recombinant murine 
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IL-13, anti-mouse eotaxin, biotinylated anti-mouse eotaxin, and recombinant murine 
eotaxin (R&D Systems, Minneapolis, MN, USA); avidin-horseradish peroxidase 
(HRP), biotinylated anti-mouse IgE, biotinylated anti-mouse IgG1, biotinylated anti-
mouse IgG2a, cell strainer, fluorescein isothiocyanate (FITC)-conjugated anti-CD4 
antibody, FITC-conjugated anti-CD8 antibody, FITC-conjugated anti-B220 antibody, 
FITC-conjugated anti-NK1.1 antibody, OptEIATM mouse IFNγ set, OptEIATM mouse 
total IgE set, OptEIATM mouse IL-4 set, OptEIATM mouse IL-5 set, and phycoerythrin 
(PE)-conjugated anti-CD3 antibody (BD Biosciences Pharmingen, San Diego, CA, 
USA); bicinchonic acid (BCA) protein assay kit, calf serum, fetal bovine serum (FBS), 
infinityTM alanine aminotransferase (ALT) liquid stable reagent, infinityTM aspartate 
aminotransferase (AST) liquid stable reagent, RestoreTM PLUS western blot stripping 
buffer (Thermo Fisher Scientific Inc, Waltham, MA ,USA); sodium carbonate 
(Na2CO3) (Kanto Chemical, Tokoyo, Japan); absolute ethanol, isopropanol (Merck, 
Darmstadt, Germany); HistoClear, and Histomount (National Diagnostics, Atlanta, 
GA, USA); Non-fat milk powder (Nestle, Switzerland); avian myeloblastosis virus 
(AMV) reverse transcriptase, dNTP mix, polymerase chain reaction (PCR) master 
mix, and ribonuclease inhibitor (Promega, Madison, WI, USA); ethidium bromide 
(Research Organics, Cleveland, OH, USA); anti-IκB-α polyclonal antibody, anti-
phospho-IκB-α (Ser32/36) monoclonal antibody, anti-MEK1/2 polyclonal antibody, 
anti-phospho-MEK1/2 (Ser217/221) polyclonal antibody, anti-IKKβ polyclonal antibody, 
anti-phospho-IKKβ (Ser180) antibody, anti-p44/42 MAP kinase polyclonal antibody, 
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anti-phospho-p44/42 (Thr202/Tyr221) polyclonal antibody, anti-phospho-p65 (Ser536) 
monoclonal antibody, and anti-p65 polyclonal antibody (Cell Signaling Technology, 
Beverly, MA, USA); enhanced chemiluminescent (ECL) western blotting 
detection reagents, and hyperfilm (GE Healthcare, Piscataway, NJ, USA); protease 
inhibitor cocktail (complete) (Roche Diagnostics, Indianapolis, IN, USA); HRP-
conjugated anti-mouse Ig, HRP-conjugated anti-rabbit Ig, AP-conjugated anti-mouse 
Ig, and AP-conjugated anti-rabbit Ig (Dako, Glostrup, Denmark); TNF-α (BioSource, 
Camarillo, CA, USA); and nuclear extract kit, TransAMTM NF-κB p65 Kit 
(ActiveMotif, Carlsbad, CA, USA); 
3.2. Asthma mouse model 
All female BALB/c mice, 6-8 wk of age (Interfauna, East Yorkshire, UK) for this 
PhD project were ordered from center for animal resources and housed in plastic 
cages (maximum 4 mice/cage) in Animal Holding Unit in the National University of 
Singapore according to the spirit of Good Laboratory Practice. Female BALB/c mice 
are high responders in which both IgE response to OVA and airway response to 
mechacholine are easily induced (Corteling and Trifilieff, 2004). Briefly, animal 
rooms should be regulated by automatic timers to provide cycles with 12-14 hours of 
light and 10-12 hours of dark. The temperature in the animal room should range from 
18° to 26°C with an average temperature of 22°C. Maintenance diets generally 
contain 4-5% fat and 14% protein. Generally a minimum of 3 days of acclimatization 
is required for mice to adapt their new surroundings.  
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Mice were sensitized with 20 µg OVA and 4 mg Al(OH)3 in 0.1 ml saline by i.p 
on day 0 and day 14. For OVA Challenge, 0.15 g of OVA was dissolved in 15 ml of 
saline to be aerosolized by a DeVilbiss Ultra-Neb Large-Volume Ultrasonic Nebulizer 
(Sunrise Medical Respiratory Products, Somerset, PA) (Figure 3.1) . Mice were then 
challenged with 1% OVA aerosol for 30 min in a chamber on days 22, 23 and 24 
(Figure 3.1). Average OVA aerosol particle size was less than 5 µm. Saline aerosol 
was used as a negative control. We changed the cage bedding three times a week. 
Under the strict control of cage environments and without additional bacterial and 
parasites` infections, the failure rate of OVA sensitization is less than 5 %. Animal 
experiments were performed according to the Institutional Guidelines for Animal 
Care and Use Committee of the National University of Singapore. 
The GSK-3β inhibitor TDZD-8 (1, 3, and 10 mg/kg) or vehicle (10% DMSO) in 
0.1ml was given by intravenous injection through the tail vein 1 hour before each 
OVA aerosol challenge on days 22, 23 and 24 (Dugo et al., 2005). Andrographolide 
(0.1, 0.5, and 1 mg/kg) or vehicle (2% DMSO) in 0.1ml was given by i.p. injection 
twice a day (one hour before and eleven hours after each OVA aerosol challenge) on 
days 22, 23 and 24 (Xie et al., 2004). 
3.3. Measurement of AHR 
Two parameters, lung resistance (RI) and dynamic compliance (Cdyn), were 














Figure 3.1 Aerosol delivery system. The ultrasonic nebulizer was employed to 
aerosolize 1% of OVA saline solution and pump the aerosol mist into an adjacent 
chamber where the aerosolized solution was inhaled into the airways of the mice. Up 





















Figure 3.2 The Buxco system. (A) Chamber for anesthetized mice with ports to 
transducers. (B) Ventilator for supplying air to tracheostomized mice. (C) MAXⅡ 
amplifier for data acquisition. (D) BioSystem XA software with R/C analyzer to 











RI (∆P/V) is defined as the pressure driving respiration divided by air flow. Cdyn 
(∆V/∆P) refers to the distensibility of the lung and is defined as the change in volume 
of the lung produced by a change in pressure across the lung.  
AHR was measured 24 hours after the last saline or OVA challenge. Mice 
were anaesthetized by an i.p. injection of 200 µl of an anesthetic mixture (ketamine: 
medetomidine: H2O = 3: 4: 33, Parnell, Alexandria NSW, Australia & Pfizer, 
Auckland, New Zealand). Then, a vertical cut of the skin above salivary glands was 
made and tissue under skin was pulled apart until the trachea was visible. The trachea 
was isolated by the forceps, a small cut was made by the scissors, and a tube (20G) 
was inserted into the trachea. Following that, the jugular vein was isolated by blunt 
dissection, cannulated by a blunt needle (27G), and connected to a microsyringe by a 
tube for intravenous methacholine administration. The mouse was placed in whole-
body plethysmograph chamber (Buxco, Sharon, CT, USA) and ventilated 
mechanically by a ventilator (Hugo Sachs Elektronik, Harvard Apparatus, March-
Hugstetten, Germany) via the tube which was already inserted into the trachea, at a 
tidal volume of 200 µl/breath and a breathing rate of 150/minute (Figure 3.2). Airflow 
changes in the sealed chamber and pressure changes in the airway were detected by 
the respective transducers, processed by a MAXⅡ amplifier, and analyzed by the 
Biosystem XA software (Buxco, Sharon, CT, USA). Methacholine was dissolved in 
PBS and administered through the jugular vein from a starting dose of 2.7 µg/kg to a 
final dose of 2000 µg/kg. The volume per methacholine dose was approximately 20 µl. 
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Threefold-increasing concentrations of methacholine were administered at 5 min 
intervals continuously. RI and Cdyn, in response to increasing concentrations of 
methacholine, were recorded and expressed as a percentage of the respective basal 
values in response to PBS.   
3.4. Collection of bronchoalveolar lavage (BAL) fluid from mice 
In separate groups of mice, BAL fluid was collected 24 hours after the last saline 
or OVA challenge as previously described (Duan et al., 2004). Mice were 
anaesthetized by an i.p. injection of 300 µl of an anesthetic mixture (ketamine: 
medetomidine: H2O = 3: 4: 33, Parnell, Alexandria NSW, Australia & Pfizer, 
Auckland, New Zealand). Tracheotomy was carried out and a blunt needle (20G) was 
inserted into the trachea. Ice-cold PBS (0.5 ml × 3) was instilled into the lungs and a 
final volume of 1.1~1.3 ml of BAL fluid was retrieved from the lungs. According to 
preliminary experiments, BAL fluid cells retrieved from the same group were 
consistent if the final volume of BAL fluid was within the range from 1.1 to 1.3 ml.    
3.5. Total and differential BAL fluid cell counts 
The BAL fluid was centrifuged at 3000 rpm for 5 min at 4°C. Supernatant was 
collected and stored at -80°C until further experiments. The pellet was resuspended in 
200 µl of 8.5 mg/ml NH4Cl for 5 min at room temperature to remove red blood cells. 
The cell suspension was centrifuged at 3000 rpm for 5 min at 4°C and the supernatant 
was discarded. Afterwards, the cell pellet was resuspended in 200 µl of RPMI 
supplemented with 10 mg/ml BSA. A total number of viable cells was enumerated 
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using a haemocytometer (10 µl cell suspension: 10 µl 0.4% trypan blue) under a 
microscope (magnification ×200). Following the total cell count, aliquots (105 
cells/150 µl) of the cell suspension were cytospined onto a slide in a Shandon 
Cytospin 3 (Thermo Electron Corporation, Pittsburgh, PA) at 600 rpm for 10 min at 
room temperature. The BAL fluid cells were stained with a modified Wright staining 
(Duan et al., 2004). Briefly, cytospin slides were fixed and stained with 800 µl of Liu 
A for 30 sec followed by 1600 µl of Liu B for 90 sec. Differential cell count was then 
performed on a minimum of 500 leukocytes (magnification ×1000). Four types of 
inflammatory cells, namely eosinophils, macrophages, neutrophils, and lymphocytes 
were identified and their respective percentage in the total inflammatory cells was 
enumerated, based on standard morphological criteria and staining (Figure 3.3). The 
absolute number of four types of inflammatory cells was calculated by their 
percentages and total inflammatory cell count. The epithelial cells were excluded in 
the differential cell count.   
3.6. ELISA 
3.6.1. Cytokines and chemokine levels in BAL fluid 
Levels of IL-4, IL-5, IL-13, IFNγ and eotaxin in the supernatant of the BAL fluid 
were determined by ELISA (BD Biosciences Pharmingen, San Diego, CA, USA for 
IL-4 and IL-5; R&D Systems, Minneapolis, MN, USA for IL-13, eotaxin, and IFNγ) 



















Figure 3.3 Type of cells found in BAL fluid of mice. (A) Control BAL fluid collect 
from the mouse sensitized with OVA and challenged with saline; (B) BAL fluid 
collected from the mouse sensitized with OVA and challenged with OVA. Mac, 








Briefly, 50 µl of diluted capture antibody (diluted to the appropriated concentration in 
relevant coating buffer) was coated to each well of an ELISA plate (NUNC, 
Denmark). The plate was sealed with parafilm and incubated overnight at 4°C. Next 
day, the coating buffer was aspirated and the plate was washed with wash buffer (PBS 
with 0.05% Tween-20). After washing, the plate was blocked with 300 µl PBS with 
10% FBS for 2 hours. Following blocking, 50 µl of standards or BAL fluid samples 
were added into each well accordingly and incubated for 2 hours at room temperature. 
Next, after washing away the unbound samples and standards, the plate was incubated 
with biotinylated-detection antibody plus HRP for 1 hour (BD OptEIATM Kit) or with 
biotinylated-detection antibody for 1 hour followed by HRP for 45 min (R&D). 
Subsequently, after washing, 50 µl of a substrate solution was added to each well, and 
incubated for 30 min in dark, followed by addition of 50 µl stopping solution (1M 
H2SO4). Finally, the optical density of each well in the plate was read at 450 nm with 
λ correction at 570 nm within 30 min. The detection limits for the cytokines and 
chemokine used are as follows: 4 pg/ml for IL-4; 4 pg/ml for IL-5; 15.6 pg/ml for IL-
13; 15.6 pg/ml for IFNγ; and 2 pg/ml for eotaxin.  
3.6.2. Immunoglobulin levels in serum 
Blood was collected from the mouse through cardiac puncture, and allowed to 
clot by leaving at room temperature for 3 hours. The clear supernatant was collected 
as the serum, and stored at -80°C until further experiments. Serum levels of total IgE, 
OVA-specific IgE, OVA-specific IgG1 and OVA-specific IgG2a were assayed by 
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ELISA. Briefly, ELISA plate was incubated at 4°C overnight with coating buffer 
containing either 20 µg/ml OVA (for OVA-specific IgE, OVA-specific IgG1 and 
OVA-specific IgG2a) or IgE capture antibody (for total IgE measurement). Next day, 
the plate was blocked with 10% FBS in 300 µl PBS for 2 hours at room temperature. 
Following blocking, total IgE standards or diluted serum samples were added into the 
respective wells and incubated for 2 hours. Next, the respective detection antibodies 
were added and the mixtures were incubated for 1 hour. After that, HRP-conjugated 
antibody was added and incubated for 45 min, followed by substrate solution for 30 
min in the dark. Finally, the optical density of each well was read at 450 nm with λ 
correction at 570 nm within 30 min of adding stopping solution. The detection limit 
for total IgE is 2 ng/ml.  
3.7. Histology 
Lungs were isolated from the thoracic cavity 24 hours after the last OVA or 
saline challenge, fixed in 10% neutral buffered formalin solution for at least 48 hours, 
and processed in a tissue processor (Leica Microsystems, Wetzler, Germany). Briefly, 
lungs were dehydrated in a series of ethanol mixtures (70% → 80% → 90% → 100%, 
30 min each and 2 hours for 100%), and immersed in xylene for 10.5 hours. Lungs 
were infiltrated with hot paraffin for 3 h and embedded in paraffin wax. The 
specimens were then cut into 5 µm sections using a microtome (Leica Microsystems, 
Wetzler, Germany) and fixed on slides.  
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For H&E staining, slides were deparaffinized with HistoClear for 10 min and 
rehydrated in a series of ethanol to water mixtures (100%→90%→70%→water and 
each for 2 min). The sections were then stained with Harris haematoxylin for 5 min, 
washed in the distilled water, and differentiated in 0.1% acid alcohol solution for 30 
sec. The sections were washed with tap water for 5 min and counter stained with 
Eosin for 1 min. Afterwards, the sections were dehydrated in a series of ethanol 
solutions (70%→90%→100% and each for 30 sec) and immersed in HistoClear for 
10 min. Evaluation of inflammation around peribronchial and perivascular areas was 
semi-quantitatively performed in a blind manner as previously described (Myou et al., 
2003). A subjective scale (0 - 4) was assigned as follows: 0: no inflammatory cells; 1: 
occasional cuffing with few inflammatory cells; 2: most bronchi or vessels 
surrounded by a thin layer of inflammatory cells; 3: most bronchi or vessels 
surrounded by a thick layer (2 - 4 cells layer deep) of inflammatory cells; 4: most of 
bronchi or vessels surrounded by a thicker layer (more than 4 cells layer deep) of 
inflammatory cells. 
Similarly, for periodic acid Schiff (PAS) staining, slides were deparaffinized with 
HistoClear for 10 min and rehydrated in a series of ethanol to water mixtures 
(100%→90%→70%→water and each for 2 min). Then, the sections were 
sequentially immersed in the periodic acid (5 min), water (5 min), and Schiff`s 
reagent (15 min). The sections were washed with tap water for 5 min and stained in 
Gill Haematoxylin for 90 sec. Next, the sections were dehydrated in a series of 
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ethanol mixtures (70%→90%→100% and each for 2 min) and cleared with 
HistoClear for 10 min. Evaluation of mucus production or goblet cell hyperplasia was 
semi-quantitatively performed in a blind manner as previously described (Grunig et 
al., 1998). According to the percentage of PAS-positive mucin-producing cells in the 
epthelium, scores (0 - 4) were assigned as follows: 0, no goblet cells; 1, < 25%; 2, 25–
50%; 3, 50–75%; 4, > 75%. 
For both H&E and PAS staining, bronchioles with the maximum internal 
diameter two times greater than the minimum internal diameter were not used for 
analysis. The scoring of inflammatory and goblet cells was performed in 2 - 4 
preparations of each mouse and mean scores were calculated from 4 - 5 mice. 
3.8. Western blotting 
Lungs were isolated from the thoracic cavity 24 hours after the last OVA or 
saline challenge and stored in -80°C until study. Lung lobes were cut into small pieces 
using scissors and homogenized in ice-cold lysis buffer with a homogenizer 
(SilentCrusher M, Heidolph Elektro GmbH & Co, Kelheim, Genman). Lysates were 
then incubated on ice for 30 min before centrifugation (18,000g for 5 min); 
supernatants were collected, and protein concentrations were determined using a BCA 
protein assay kit. The same amount of protein (30 µg) mixed with sample buffer were 
separated by 10% SDS-PAGE in a Trans-Blot tank (Bio-Rad Laboratories, Hercules, 
CA, USA)  and transferred to a PVDF membrane using a semi-try transblotter (ATTO 
Corp, Tokyo, Japan). The PVDF membrane was blocked with 5% non-fat milk in 
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Tween-20 Tris buffered saline (TTBS) for 2 hours and probed with anti-phospho-p65 
(Ser536), or anti-p65 antibodies for 2 hours. The PVDF was then washed with TTBS 
for 10 times (2 - 3 min each), and incubated in HRP-conjugated anti-rabbit or anti-
mouse antibodies for one hour before being developed on hyperfilms using an ECL 
reagent. After washing several times in TTBS, ECL reagent was removed with 
western blot stripping buffer. Subsequently, the PVDF was blocked again, reprobed 
with anti-β-actin antibody, and developed using an AP substrate kit. Blots were 
quantitated using Gel-Pro v3.1 imaging software (Media Cybernetics, Silver Spring, 
MD, USA).  
3.9. Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
Lungs were isolated from the thoracic cavity 24 hours after the last OVA or 
saline challenge and stored in RNAlater at -80°C. Before RNA isolation, lung tissues 
were removed from the RNAlater with sterile forceps, immersed in 1 ml Trizol, and 
homogenized on ice using the homogenizer. Then, RNA isolation was performed 
using Trizol according to the instructions from Invitrogen. After dissolving the 
isolated RNA in DEPC water, the spectrophotometer (NanoDrop ND-1000, Thermo 
Fisher Scientific Inc, Waltham, MA, USA) was used to quantify the amount and 
purity of the RNA present in the sample. Both A260/A280 (DNA/protein) and 
A260/A230 (DNA/organic contaminants) ratio were recorded as an indicator of purity 
of RNA. An acceptable level of purity for RNA extracts should be around 1.9 to 2.1 
for both A260/A280 and A260/A230 ratio. Then, cDNA was synthesized from 1 µg 
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of isolated RNA by a random primer and AMV reverse transcriptase using a 
multiwell thermal cycler (GeneAmp PCR system 2700, Applied Biosystems, Foster 
City, CA, USA). PCR amplifications were then performed on 1 µl of cDNA template 
in a 25 µl reaction volume containing 12.5 µl of 2× PCR master mix (50 units/ml 
TaqDNA polymerase, 400 µM dATP, 400 µM dGTP, 400 µM dCTP, 400 µM dTTP, 
and 3 mM MgCl2), 9.5 µl nuclease-free water, 1 µl forward primer (10 µM) and 1 µl 
reverse primer (10 µM) using the multiwell thermal cycler. Primers used in the PCR 
reactions are listed in Table 3.1. PCR products underwent electrophoresis on 1.5% 
agarose gels stained with ethidium bromide (100 V, 30 min) and were visualized 
under an ultraviolet transilluminator. Furthermore, β-actin was used as a 
housekeeping gene to normalize variations between sample loadings. 
3.10. Alanine and aspartate aminotransferase assay 
Blood was collected from the mouse through cardiac puncture, and allowed to 
clot by leaving at room temperature for 3 hours. The clear supernatant was collected 
as the serum, and stored at -80°C until further experiments. Serum ALT and AST 
activities were measured using a kinetic spectrophotometric assay according to the 
manufacturer’s instructions. Briefly, serum samples were kept at room temperature at 
least 3 days before the experiments. 10 µl sample and 100 µl ALT or AST reagents 
were mixed in 96 well plates and incubated for 30 seconds. Afterwards, absorbance 
value of each well was read at 340 nm with λ correction at 405 nm after exactly 1, 2, 
and 3 min, with constant temperature (37°C).  
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Table 3.1 Primer Sets for RT-PCR 
Targets  
(Accession ID) 























































































5’- GAGCTCCTCCAGACGGGTAGGCTTG -3’  





5’- CAGGAGAAGATTCCAAAGAT -3’ 
5’- ACTGGTTCTGTGCCTGCAGC -3’ 












































Activities of AST or ALT were calculated by the change in absorbance per min from 
the linear portion of the reaction curve (∆absorbance/min*factor).  
3.11. NF-κB transcription factor assay 
Lungs were collected 24 hours after the last OVA or saline challenge and 
stored at -80°C until further study. Lungs were homogenized on ice using the 
homogenizer and nuclear fractions were isolated with an Active Motif nuclear extract 
kit according to the instructions from the manufacturer.Protein concentrations of the 
nuclear extracts were determined by the BCA protein assay. NF-κB DNA-binding 
activity was analyzed using the TransAMTM NF-κB p65 transcription factor assay kit 
following the manufacturer’s protocol. Briefly, this kit contains a 96-well plate with 
immobilized oligonucleotide containing the NF-κB consensus binding sequence (5'-
GGGACTTTCC-3'). Nuclear extracts (5 µg) were incubated in the wells for 1 hour 
and anti-p65 primary antibodies were then added into the wells following washing. A 
HRP-conjugated secondary antibody was subsequently added to detect the bound 
primary antibody. Developing solution and stoping solution were used to develop a 
colorimetric reaction. The absorbance was measured at 450 nm with a reference 
wavelength of 655 nm by a microplate reader (Tecan group Ltd. Mannedorf, 
Switzerland). In addition, the wild-type or mutated NF-κB consensus oligonucleotide 
was added into the reactions as the competitive or mutated competitive control.  
3.12. Cell cultures 
3.12.1.    Lymphocyte recall experiments 
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Bronchial lymph nodes (3 - 4 nodes per mouse) were isolated from the lungs 
aseptically and passed through cell strainers to prepare a single-cell suspension. Cells 
were cultured at 2×106 cells/ml in RPMI 1640 medium supplemented with 2 mM L-
glutamine, 100 IU/ml penicillin, 100 µg/ml streptomcin, 25 mM HEPES buffer, and 
10% heat-inactivated FCS. Cells were cultured in medium only, or with 200 µg/ml 
OVA. Con-A (10 µg/ml) was treated as a positive control. After 72 hours’ incubation, 
the supernatants from triplicate cultures were collected at -80°C until analysis of 
cytokine concentrations by ELISA.  
3.12.2.    Normal human bronchial epithelial cells 
Normal human bronchial epithelial cells (Cambrex BioScience, Walkersville, 
MD, USA) were grown in bronchial epithelial bulletkit medium (Cambrex 
BioScience, Walkersville, MD, USA) supplemented with bovine pituitary extract (2 
ml), hydrocortisone (0.5 ml), recombinant human EGF (0.5 ml), epinephrine (0.5 ml), 
transferring (0.5 ml), insulin (0.5 ml), retinoic acid (0.5 ml), triiodothyronine (0.5 ml), 
gentamycin sulfate (50 µg/ml), and amphotericin B (50 ng/ml) in 5% CO2 incubator 
at 37°C, and subcultured at 80% to 85% confluency. One million cells were seeded 
onto the 100 mm cell culture plate 24 hours before the experiments. Cells were 
pretreated with 10 µM TDZD-8 or vehicle (0.05% DMSO) 1 hour before stimulation 
with 10 ng/ml TNF-α. Total protein and mRNA were extracted from cells 24 hours 
later.  
3.12.3.    A549 cells 
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A549 cells (human lung epithelial cell line, CCL - 185, American Type Culture 
Collection, Manassas, VA, USA) were cultured in RPMI with 10% FBS in 5% CO2 
incubator at 37°C, and subcultured at 80% to 85% confluency. One million of cells 
were seeded onto the 100 mm cell culture plate 24 hours before the experiments. Cells 
were pretreated with 30 µM andrographolide or vehicle (0.1% DMSO) for 4 hours 
before stimulation with 10 ng/ml TNF-α. The incubation time and andrographolide 
dose was determined by preliminary optimizing experiments. Total protein or nuclear 
protein was extracted at different time points and stored at -80°C until further 
experiments.  
3.13. Statistical analysis   
All data are presented as means ±  SEM. One-way ANOVA followed by 
Dunnett`s test was used to determine significant difference between different groups 
using SPSS15 for windows (SPSS Inc, Chicago, IL, USA). The critical level for 





















4. ANTI-INFLAMMATORY EFFECTS OF A GLYCOGEN SYNTHASE 












4.1.1. Effects of TDZD-8 on OVA-induced eosinophil recruitment in BAL 
fluid 
BAL fluid was collected 24 h after the last OVA or saline aerosol challenge, 
and total and differential cell counts were performed. We excluded the epithelial 
cells when we did the differential cell counts. In saline control mice, almost all 
BAL fluid leukocytes are macrophages. OVA inhalation significantly (P < 0.05) 
increased total cell, eosinophil and lymphocyte counts as compared with saline 
control (Figure 4.1). In contrast, macrophage and neutrophil counts were not 
significantly affected (Figure 4.1). TDZD-8 (1, 3 and 10 mg/kg) substantially 
reduced the total cell, eosinophil, and lymphocyte counts in BAL fluid in a dose-
dependent manner as compared with the DMSO vehicle control (Figure 4.2). 
These results clearly suggest a possible role of GSK-3β inhibitor in eosinophil and 
lymphocyte recruitment during airway allergic inflammation. Flow cytometric 
analysis revealed that peripheral blood leukocytes from saline-challenged, OVA-
challenged, vehicle control, and TDZD-8-treated mice had similar percentages of 
CD3+, CD4+, CD8+ T cells, B cells (B220), and NK cells (NK1.1) (Figure 4.3). 
Hence, inhibition of eosinophil and lymphocyte pulmonary recruitment is unlikely 
due to any potential non-specific cytotoxic effects of TDZD-8. 














Figure 4.1 Differential cell counts in BAL fluid. Inflammatory cell counts in BAL 
fluid obtained from sensitized mice 24 hours after the last saline aerosol or OVA 
aerosol challenge. Differential cell counts were performed on a minimum of 500 
cells to identify eosinophil (Eos), macrophage (Mac), neutrophil (Neu), and 
lymphocyte (Lym). Number of mice tested in each treatment group is shown as n 
value in parentheses. *Significant difference from saline control, P < 0.05. 




































Figure 4.2 Effects of TDZD-8 on BAL fluid cell infiltration. TDZD-8 reduced 
OVA-induced inflammatory cell counts in BAL fluid from sensitized mice 24 
hours after the last OVA aerosol challenge. Differential cell counts were 
performed on a minimum of 500 cells to identify eosinophil (Eos), macrophage 
(Mac), neutrophil (Neu), and lymphocyte (Lym). Number of mice tested in each 
treatment group is shown as n value in parentheses. *Significant difference from 













































Figure 4.3 Effects of TDZD-8 on peripheral blood mononuclear cell (PBMC). 
Plasma was collected 24 hours after the last OVA or saline aerosol challenge. 
Expressions of (A) CD3, (B) CD4, (C) CD8, (D) NK1.1 and (E) B220 on PBMC 
were analyzed using FACS (n = 3 mice per group). The dose of TDZD-8 was 10 
mg/kg. Values shown are the mean ± SEM. *Significant difference from DMSO 
































































































































Lung tissue was collected 24 h after the last OVA challenge. OVA aerosol 
challenge induced marked infiltration of inflammatory cells into the 
peribronchiolar and perivascular connective tissues as compared to saline 
challenge (Figure 4.4 A and B). The majority of the infiltrated inflammatory cells 
were eosinophils.TDZD-8 (10 mg/kg) markedly attenuated the eosinophil-rich 
leukocyte infiltration as compared to DMSO control (Figure 4.4 C, D and I). On 
the other hand, OVA-challenged mice, but not saline-challenged mice, developed 
marked goblet cell hyperplasia and mucus hypersecretion within the bronchi in the 
lung (Figure 4.4 E and F). The OVA-induced mucus secretion was significantly 
attenuated by TDZD-8 (10 mg/kg) as compared to the DMSO control (Figure 4.4 
G, H and J).   
4.1.3. Effects of TDZD-8 on cytokine levels in BAL fluid  
To determine the cytokine levels in the lung, IL-4, IL-5, IL-13 and eotaxin 
amounts in BAL fluid were measured using ELISA. As shown in Figure 4.5, OVA 
inhalation in sensitized mice substantially induced IL-4, IL-5, and IL-13 release 
into BAL fluid as compared with saline control. OVA moderately increased BAL 
fluid eotaxin level. TDZD-8 significantly (P < 0.05) decreased IL-5, IL-13 and, to 
a lesser extent, eotaxin levels in BAL fluid as compared with DMSO control 
(Figure 4.5 and Figure 4.6). In contrast, TDZD-8 had no effect on IL-4 levels in 
BAL fluid (Figure 4.5 A).   




















Figure 4.4 A-D, I Effects of TDZD-8 on lung tissue inflammatory cell infiltration. 
Histologic examination of lung tissue eosinophilia (A, B, C, and D, magnification 
×400) 24 hours after the last challenge of saline aerosol (A), OVA aerosol (B), 
OVA aerosol plus DMSO (C), or OVA aerosol plus 10 mg/kg TDZD-8 (D). 
Quantitative analyses of inflammatory cell infiltration in lung sections were 
performed as described in chapter 3. Scoring of inflammatory cells was performed 
in at least three different fields for each lung section. Mean scores were obtained 




































Figure 4.4 E-H, J Effects of TDZD-8 on mucus production. Histologic 
examination of mucus secretion (E, F, G, and H, magnification ×400) 24 hours 
after the last challenge of saline aerosol (E), OVA aerosol (F), OVA aerosol plus 
DMSO (G), or OVA aerosol plus 10 mg/kg TDZD-8 (H). Quantitative analyses of 
mucus production (J) in lung sections were performed as described in chapter 3. 
Scoring of goblet cells was performed in at least three different fields for each 
lung section. Mean scores were obtained from four animals. *Significant 
























Figure 4.5 Effects of TDZD-8 on Th2 cytokines levels in BAL fluid. BAL fluids 
were collected 24 hours after the last OVA aerosol challenge. The saline group 
refers to mice which were sensitized with OVA and challenged with saline. The 
OVA group refers to asthmatic mice which were both sensitized and challenged 
with OVA. The DMSO group indicates asthmatic mice which were treated with 
the drug solvent, DMSO. The 1, 3, and 10 groups indicate asthmatic mice which 
were treated with three different doses of TDZD-8 (1 = 1 mg/kg, 3 = 3 mg/kg, and 
10 = 10 mg/kg). Levels of (A) IL-4, (B) IL-5, and (C) IL-13 were analyzed using 
ELISA (n = 5 mice per group). Values shown are the mean ± SEM. *Significant 













Figure 4.6 Effects of TDZD-8 on eotaxin level in BAL fluid. BAL fluids were 
collected 24 hours after the last OVA aerosol challenge. The saline group refers to 
mice which were sensitized with OVA and challenged with saline. The OVA 
group refers to asthmatic mice which were both sensitized and challenged with 
OVA. The DMSO group indicates asthmatic mice which were treated with the 
drug solvent, DMSO. The 1, 3, and 10 groups indicate asthmatic mice which were 
treated with three different doses of TDZD-8 (1 = 1 mg/kg, 3 = 3 mg/kg, and 10 = 
10 mg/kg). The levels of eotaxin was analyzed using ELISA (n = 5 mice per 
group). Values shown are the mean ± SEM. *Significant difference from DMSO 












In order to evaluate whether TDZD-8 could modify an ongoing OVA-specific Th2 
response in vivo, levels of total IgE and OVA-specific IgE were determined using 
ELISA. Substantial elevation in total IgE and OVA-specific IgE were observed in 
serum from OVA sensitized and challenged mice as compared to saline-challenged 
mice (Figure 4.7). TDZD-8 significantly (P < 0.05) lowered OVA-specific IgE 
levels at all three doses tested (Figure 4.7 A), but had no effect on the levels of 
total IgE (Figure 4.7 B), indicating an OVA-specific inhibition at the antigen 
presentation level or at the T cell- B cell interaction level Th2 response by the 
GSK-3β inhibitor. 
4.1.5.  Effects of TDZD-8 on lung mRNA expression of inflammatory markers 
OVA aerosol challenge markedly up-regulated the mRNA levels of adhesion 
molecules ICAM-1 and VCAM-1 which are pivotal for pulmonary inflammatory 
cell recruitment such as eosinophils and lymphocytes (Jia et al., 1999); Muc5ac 
which is essential for mucin production (Zuhdi Alimam et al., 2000); and of the 
chitinase family members (acidic mammalian chitinase [AMCase], Ym1 and Ym2) 
which have recently been shown to play critical roles in airway inflammation and 
remodeling (Webb et al., 2001; Zhao et al., 2005; Zhu et al., 2004). Pre-treatment 
with TDZD-8 (10 mg/kg) moderately decreased OVA-induced ICAM-1, VCAM-1, 
and AMCase mRNA expression but dramatically suppressed Muc5ac, Ym1, and 
















Figure 4.7 Effects of TDZD-8 on serum IgE production. Mouse serum was 
collected 24 hours after the last OVA aerosol challenge. The saline group refers to 
mice which were sensitized with OVA and challenged with saline. The OVA 
group refers to asthmatic mice which were both sensitized and challenged with 
OVA. The DMSO group indicates asthmatic mice which were treated with the 
drug solvent, DMSO. The 1, 3, and 10 groups indicate asthmatic mice which were 
treated with three different doses of TDZD-8 (1 = 1 mg/kg, 3 = 3 mg/kg, and 10 = 
10 mg/kg). The levels of (A) OVA specific IgE and (B) total IgE were analyzed 
using ELISA (n = 6 mice per group). Values shown are the mean ± SEM. 



















Figure 4.8 Effects of TDZD-8 on pulmonary mRNA expression of inflammatory 
markers. Lung tissues were collected 24 hours after the last OVA aerosol 
challenge. Total mRNA was extracted using TriZol reagent and the PCR products 
were separated in a 2% agarose gel visualized under ultraviolet light. β-actin was 
used as an internal control. The experiments were repeated for three times (n = 3 










4.1.6. Effects of TDZD-8 on OVA-induced AHR in mice  
To investigate the effect of GSK-3β inhibition on AHR in response to 
increasing concentrations of methacholine, we measured both RI and Cdyn in 
mechanically ventilated mice with and without pretreatment of TDZD-8. As 
compared to saline-challenged group, OVA-challenged mice developed AHR 
which was typically reflected by high RI (Figure 4.9) and low Cdyn (Figure 4.10). 
TDZD-8 (10 mg/kg) dramatically suppressed AHR in OVA-challenged mice in 
response to methacholine, suggesting that Th2 immune responses and airway 
inflammation in vivo was modified (Figure 4.9 and Figure 4.10). DMSO did not 
show any inhibitory effects on AHR in OVA-challenged mice (Figure 4.9 and 
Figure 4.10).   
4.1.7. Immunoblot analysis of lung NF-κB p65 
To verify that the inhibitory effects of TDZD-8 on the mouse asthma model 
were mediated by NF-κB p65 inhibition in vivo, we examined the effects of 
TDZD-8 on OVA-induced NF-κB subunit p65 phosphorylation (Ser536) in lungs 
isolated from mice treated with DMSO or 10 mg/kg TDZD-8. At 24 hours after 
the last OVA aerosol challenge, the extent of p65 (Ser536) phosphorylation was 
similar to the one in saline-challenged control mice (data not shown). This likely 
implies that the phosphorylation event has already returned to basal level by 24 
hours. Therefore, we tested the p65 (Ser536) phosphorylation 2 hours after the last 










Figure 4.9 Effects of TDZD-8 on airway resistance. Airway responsiveness of 
mechanically ventilated mice in response to intravenous methacholine was 
measured 24 hours after the last saline aerosol or OVA aerosol with pretreatment 
of either DMSO or 10 mg/kg TDZD-8. AHR is expressed as percentage change 
from the baseline level of lung resistance (RI). Number of mice tested in each 
treatment group is shown as n value in parentheses. *Significant difference from 





















Figure 4.10 Effects of TDZD-8 on airway dynamic compliance. Airway 
responsiveness of mechanically ventilated mice in response to intravenous 
methacholine was measured 24 hours after the last saline aerosol or OVA aerosol 
with pretreatment of either DMSO or 10 mg/kg TDZD-8. AHR is expressed as 
percentage change from the baseline level of lung dynamic compliance (Cdyn). 
Number of mice tested in each treatment group is shown as n value in parentheses. 











At this point, we were able to capture a significant ( P < 0.05, when compared 
with saline- challenged mice) increase in p65 phosphorylation in the lung lysates 
from OVA-challenged mice, and this increase in p65 phosphorylation was 
significantly (when compared with DMSO vehicle control) inhibited by TDZD-8 
(Figure 4.11). Total levels of NF-κB subunit p65 in lungs were not altered at all by 
GSK-3β inhibition. Equal loading of proteins was confirmed using β-actin as an 
internal control.  
4.1.8 Effects of TDZD-8 on TNF-α stimulated human bronchial epithelial cells 
To further characterize the anti-inflammatory effects of GSK-3β inhibition 
in a relevant airway cell type, we studied the effects of TDZD-8 on TNF-α (10 
ng/ml) induced phosphorylation of NF-κB subunit p65 and cytokine mRNA 
expression in normal human bronchial epithelial cells. TNF-α has been implied to 
play a critical role in asthma (Erin et al., 2006; Hart et al., 1998) and is a potent 
stimulator of human airway epithelial cells (Newton et al., 2007). TNF-α 
drastically increased the p65 (Ser536) phosphorylation, but did not affect the level 
of total p65 protein in normal human bronchial epithelial cells (Figure 4.12). TNF-
α also up-regulated the mRNA level of proinflammatory cytokines, such as IL-6, 
IL-8, MCP-1, and RANTES, in cells (Figure 4.13). TDZD-8 (10 µM) markedly 
blocked TNF-α induced p65 (Ser536) phosphorylation as well as the up-regulation 
of IL-6, IL-8, MCP-1, and RANTES in normal human bronchial epithelial cells 



















Figure 4.11 Effects of TDZD-8 on NF-κB subunit p65 phosphorylation in lung 
tissue. Western blot analysis of p65 phosphorylation at Ser536 in lung fragments 
isolated from mice 2 hours after the last saline aerosol or OVA aerosol challenge 
pretreated with either DMSO or 10 mg/kg TDZD-8. Proteins (10 µg per lane) were 
separated by SDS-PAGE and probed with anti-p65 or anti–phospho-p65 antibody. 
The blot was developed by enhanced chemiluminescence reagent and quantitated 
using Gel-Pro imaging software. β-actin was used as an internal control. Values 
shown are the mean ± SEM of three separate experiments. *Significant difference 






















Figure 4.12 Effects of TDZD-8 on TNF-α-induced phosphorylation of p65 in 
normal human bronchial epithelial cells. Primary epithelial cells were stimulated 
with 10 ng/ml TNF-α for 24 hours, with or without pretreatment of 10 µM TDZD-
8. Western blot analysis of p65 phosphorylation at Ser536 in human bronchial 
epithelial cells. Proteins (10 µg per lane) were separated by SDS-PAGE and 
probed with anti-p65 or anti–phospho-p65 antibody. The blot was developed by 
ECL reagent and quantitated using Gel-Pro imaging software. β-actin was used as 
an internal control. Values shown are the mean ± SEM of three separate 





















Figure 4.13 Effects of TDZD-8 on TNF-α-induced expressions of 
proinflammatory cytokines in normal human bronchial epithelial cells. Primary 
epithelial cells were stimulated with 10 ng/ml TNF-α for 24 hours, with or without 
pretreatment of 10 µM TDZD-8. Total mRNA was extracted using TriZol reagent 
and the PCR products were separated in a 2% agarose gel visualized under 
ultraviolet light. β-actin was used as an internal control. This is a representative 












GSK-3β is a serine-threonine kinase that is constitutively active in cells 
(Cohen and Frame, 2001). Besides its role in glycogen metabolism, GSK-3β also 
acts as a key regulator in numerous signaling pathways initiated by diverse stimuli. 
The most well established role of GSK-3β is in the WNT/β-catenin pathway, 
which is essential for the specification of cell fates during embryogenesis (Huang 
and He, 2008). In resting cells, GSK3 forms a protein complex with Axin and β-
catenin in the cytosol, leading to the phosphorylation and degradation of β-catenin 
(Ciani and Salinas, 2005). Activation of WNT pathway inhibits GSK3 in the 
complex, causing the translocation of β-catenin into the nucleus, where it interacts 
with T-cell factor to initiate the expression of targeted genes, including oncogenes 
as cycline D1, Myc, and c-jun (Polakis, 1999). Furthermore, mutations in β-
catenin, which render it resistant to degradation, are commonly associated with 
several types of cancers, particularly colon cancer (Lustig and Behrens, 2003). 
Therefore, one major concern regarding to the long-term use of GSK-3 inhibitors 
is their contribution to tumorigenesis due to the accumulation of proto-oncogenes. 
However, no inactivating mutations in GSK3 have been found yet in human 
cancers, contrasting with the fact that many mutations have been found in human 
cancers in the other components of WNT pathway (Lustig and Behrens, 2003; 
Polakis, 1999). Moreover, lithium, the best characterized GSK-3 inhibitor, has 
been used to treat bipolar diseases for many years, and their long term use has not 
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been associated with increased risks of cancer (Cohen et al., 1998; Jope, 2003). 
These findings suggest that inhibition of GSK-3 might not be sufficient to increase 
the levels of β-catenin in primary cells and induce cancers.  
GSK-3β has recently been linked to the regulation of NF-κB transactivation 
function in a study using GSK-3β knockout mice (Hoeflich et al., 2000). It has 
been demonstrated that NF-κB activity is up-regulated in allergic airway 
inflammation both in human and in animal models of asthma (Broide et al., 2005; 
Donovan et al., 1999; Gagliardo et al., 2003; Hart et al., 1998; Poynter et al., 
2004). Various therapeutic strategies targeted at the NF-κB signaling pathway 
such as NF-κB specific decoy oligonucleotide (Desmet et al., 2004), p65-specific 
antisense oligonucleotide (Choi et al., 2004), and IKK-2 selective small molecule 
inhibitors (Birrell et al., 2005) have demonstrated beneficial effects in 
experimental asthma models. Cumulative evidence shows that GSK-3β can 
phosphorylate the p65 subunit, particularly the COOH-terminus of p65 at Ser536, 
to enhance transcriptional responses of NF-κB (De Ketelaere et al., 2004; Hoeflich 
et al., 2000; Schwabe and Brenner, 2002). Hence, pharmacologic inhibition of 
GSK-3β may lead to inhibition of NF-κB transcriptional activity and offer the 
anti-inflammatory potential. Due to the discoveries of both crystal structure and 
phosphorylation mechanisms of GSK-3β, it is possible to design a specific 
inhibitor of GSK-3β (Dajani et al., 2001; ter Haar et al., 2001). TDZD-8 is the first 
highly specific non-ATP competitive GSK-3β inhibitor with micromolar range of 
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the IC50 value and negligible effect against other protein kinases such as protein 
kinase A, protein kinase C, casein kinase-II, and cyclin-dependent kinase-1 
(Martinez et al., 2002; Meijer et al., 2004). Structure activity relationship studies 
have suggested that the thiadiazolidinone ring in the TDZD-8 compound may be 
crucial to the inhibition of GSK-3β (Martinez et al., 2002). Therefore, TDZD-8 is 
a suitable compound for us to study the effects of inhibition of GSK-3β in the 
allergic inflammation. Our immunoblot analysis revealed a significant inhibition 
of p65 phosphorylation (Ser563) by TDZD-8 in OVA-challenged lungs and in 
TNF-α stimulated human bronchial epithelial cells, confirming that inhibition of 
GSK-3β suppressed NF-κB signaling pathway in inflamed airways and in primary 
bronchial epithelial cell culture. However, our preliminary study using ELISA to 
measure lung tissue nuclear extract NF-κB binding activity to DNA revealed that 
TDZD-8 had no effect on the binding of NF-κB to DNA motif. Taken together, in 
our mouse asthma model, TDZD-8 attenuated p65 phosphorylation without 
affecting NF-κB to DNA-binding. Our observation is supported by Hoeflich and 
colleagues (Hoeflich et al., 2000), Martin and coworkers (Martin et al., 2005), and 
Dugo and associates (Dugo et al., 2005), but not by Eto and colleagues (Eto et al., 
2005). The reason for the observed differences is not clear, but may be related to 
the disease models used or the doses and pharmacokinetics of the inhibitors 
employed. 
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Th2 cells play an essential role in the pathogenesis of the allergic airway 
inflammation (Herrick and Bottomly, 2003). IL-4, IL-5, and IL-13 can be 
produced by various resident cells such as bronchial epithelial cells, tissue mast 
cells, and alveolar macrophages, as well as by infiltrated inflammatory cells such 
as lymphocytes and eosinophils. NF-κB is a critical transcription factor for Th2 
cell differentiation (Das et al., 2001). Our present results show that TDZD-8 
significantly reduced the levels of IL-5, IL-13, and eotaxin in BAL fluids from 
OVA-challenged mice. These findings are consistent with those from OVA-
challenged mice with disrupted NF-κB function via conditional knockout of IKKβ 
or transgenic IκBα mutant expression selectively in airway epithetlium (Broide et 
al., 2005; Poynter et al., 2004), or via aerosol administration of NF-κB decoy 
oligonucleotide(Desmet et al., 2004), suggesting that TDZD-8 may exert its anti-
inflammatory action on airway epithelium. In addition, antigen receptor activation 
in T and B cells and in mast cells has been shown to culminate in NF-κB 
activation (Li et al., 2004; Peng et al., 2005; Weil and Israel, 2004), and TDZD-8 
may modulate NF-κB mediated cytokine production in these inflammatory cells. 
In addition, airway smooth muscle is another source of proinflammatory cytokines 
during the airway inflammation (Howarth et al., 2004). Repression of NF-κB 
signaling pathway has been shown to block IL-13 induced eotaxin production in 
cultured human airway smooth muscle cells (Birrell et al., 2005). As such, the 
observed reduction of IL-5, IL-13, and eotaxin levels in BAL fluid from GSK-3β 
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inhibitor TDZD-8 treated mice may be due to inhibition of NF-κB activation in 
those inflammatory and airway resident cells. Surprisingly, after the treatment of 
TDZD-8, IL-4 levels in BAL fluid were not affected. However, previous studies 
also found similar phenomenon which has shown no change in IL-4 levels in BAL 
fluid in murine models by IκBα mutant mice or by the treatment of NF-κB decoy 
oligodeoxynucleotides, respectively (Desmet et al., 2004; Poynter et al., 2004). 
This may be due to the lack of κB site in IL-4 gene or incomplete inhibition of 
NF-κB pathways, and more studies should be done to elucidate mechanisms. 
Another possible explanation is the limitation of IL-4 ELISA assay in which there 
is a minor gap between negative mice and asthmatic mice, and levels of IL-4 in 
BAL fluid is close to the lowest detection level.   
Eosinophils play a central role in the pathogenesis of allergic inflammation 
(Rothenberg and Hogan, 2006). Our present findings showed that TDZD-8 
prevented eosinophil infiltration into the airways as shown by a significant drop in 
total cell counts and eosinophil counts in BAL fluid, and in tissue eosinophilia in 
lung sections. Eosinophil transmigration into the airways is a multistep process 
that is orchestrated by cytokines such as IL-5 and IL-13, and coordinated by 
specific chemokines such as eotaxin in combination with adhesion molecules such 
as ICAM-1 and VCAM-1 (Jia et al., 1999; Ono et al., 2003; Rothenberg and 
Hogan, 2006). IL-13 is by far the most potent inducer of eotaxin expression in 
airway epithelial cells (Li et al., 1999). We demonstrated that TDZD-8 slightly 
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down-regulated the expression of VCAM-1 and ICAM-1 mRNA in OVA-
challenged lungs. These findings are likely to be due to TDZD-8–mediated NF-κB 
inhibition, as genes for VCAM-1 and ICAM-1 contain the κB site for NF-κB 
within their promoters (Holden et al., 2004; Kumar et al., 2004). Taken together, 
the observed reduction in airway eosinophilia by GSK-3β inhibitor TDZD-8 may 
be a result of composite inhibitory effects on IL-13 and eotaxin production, and on 
VCAM-1 and ICAM-1 expression, secondary to inhibition of NF-κB activation. 
We have also demonstrated a dramatic reduction in mucus production in 
TDZD-8–treated mice as compared with DMSO control. Cumulative evidence 
indicates that IL-5 and IL-13 play a critical role in goblet cell hyperplasia and 
mucin Muc5ac gene and protein expression in mice (Justice et al., 2002; Zuhdi 
Alimam et al., 2000). Interestingly, Muc5ac gene expression is dependent on the 
transcriptional activity of NF-κB (Lora et al., 2005), and selective ablation of NF-
κB function in airway epithelium blocked OVA-induced mucus production in mice 
(Broide et al., 2005). We also observed a dramatic drop in Muc5ac mRNA 
expression by TDZD-8 in OVA-challenged lungs. As such, the marked decrease in 
mucus production in TDZD-8 treated lungs may be attributed to a substantial drop 
in IL-5 and IL-13 levels, and a direct inhibitory action on NF-κB in airway 
epithelium in asthmatic mice treated with the GSK-3β inhibitor. Elevated serum 
IgE levels are a hallmark of the Th2 immune response. Our data showed that 
serum levels of OVA-specific IgE were substantially reduced by TDZD-8. NF-κB 
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plays a crucial role in B cell receptor–induced proliferation of mature B cells (Li 
et al., 2004; Weil and Israel, 2004). In addition, IL-13 is important in directing B 
cell growth, differentiation, and secretion of IgE (Emson et al., 1998; Wills-Karp, 
2004). The biological activities of IgE are mediated through its interaction with 
FcεRI on mast cells and basophils. Cross-linking of FcεRI initiates multiple 
signaling cascades leading to NF-κB activation and production of cytokines and 
chemokines (Lorentz et al., 2003; Peng et al., 2005). Therefore, the observed 
reduction in serum OVA-specific IgE by TDZD-8 in our asthma model may be 
contributed by its inhibitory effects on B cell activation and on IL-13 production 
by inflammatory cells such as mast cells, secondary to inhibition of NF-κB 
activation. 
A family of chitinase proteins including AMCase, Ym1, and Ym2 has recently 
been found to be markedly elevated in allergic airway inflammation and to play a 
role in the pathogenesis of asthma (Zhao et al., 2005; Zhu et al., 2004). They are 
mainly expressed in airway epithelium and alveolar macrophages. A recent study 
demonstrated an increase in AMCase levels in a mouse asthma model and in 
subjects with asthma in an IL-13 dependent manner (Zhu et al., 2004). When 
given intratracheally, IL-13 elevated Ym1 and Ym2 levels in BAL fluid from mice 
in vivo (Webb et al., 2001). Although the molecular mechanisms of action of 
chitinases in asthma are largely unknown, they can specifically bind to 
carbohydrate moieties such as GlcN oligomers and other glycosaminoglycans such 
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as heparin and heparan sulfate to regulate eosinophil chemotaxis, inflammation, 
and tissue remodeling (Elias et al., 2005; Zhu et al., 2004). Our data show that 
TDZD-8 slightly down-regulated AMCase, moderately inhibited Ym1, but 
dramatically suppressed Ym2 mRNA levels in OVA-challenged lungs. The 
reduction of chitinases, especially Ym2, by TDZD-8 may be a result of the major 
drop in IL-13 level in the airways (of animals treated with TDZD-8) and 
contribute to the diminished pulmonary eosinophilia. 
It is believed that inflammatory mediators released during the allergic 
inflammation play a critical role in AHR development (Cohn et al., 2004; 
Fernandes et al., 2003). We report here that TDZD-8 significantly inhibited OVA-
induced AHR to increasing concentrations of methacholine. It has been 
established that IL-5 plays a critical role in AHR by mobilizing and activating 
esoinophils, leading to the release of pro-inflammatory products such as major 
basic protein and cysteinyl-leukotrienes, which are closely associated with AHR 
(Rothenberg and Hogan, 2006). In addition, IL-13 has been shown to induce AHR 
in mouse asthma models in which cysteinyl-leukotrienes have been implicated in 
AHR (Vargaftig and Singer, 2003; Wills-Karp, 2004). Moreover, IgE-mediated 
mast cell activation may contribute to AHR by producing a wide array of 
inflammatory mediators and cytokines (Lorentz et al., 2003). Thus, the observed 
reduction of AHR by GSK-3β inhibition may be associated with reduction in Th2 
cytokine production, tissue eosinophilia, and serum IgE level by TDZD-8. 
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Allergic airway inflammation and AHR development involve multiple 
inflammatory cells and a wide array of mediators. We report here for the first time 
that GSK-3β inhibition effectively reduced OVA-induced IL-5, IL-13 and eotaxin 
production, pulmonary eosinophilia, serum IgE synthesis, mucus hypersecretion, 
and AHR in a mouse asthma model. These findings support a potential role for 
GSK-3β inhibitor in the treatment of asthma via the inhibition of NF-κB p65 
phosphorylation. 
However, there are still many discrepancies between asthma patients and 
mouse models which are difficult to reconcile. For example, asthmatic mice 
exhibit only transient mechacholine-induced AHR, whereas asthma patients show 
signs of both transient and consistent AHR. The asthma model used in this study is 
an acute mouse model, while most of asthma patients are induced by chronic 
allergen exposure. Therefore, it remains uncertain whether it is a potential and 
useful therapy for human patients. More studies confirming the known effects of 













5. ANTI-INFLAMMATORY EFFECTS OF ANDROGRAPHOLIDE IN 












5.1.  Results 
5.1.1.  Effects of andrographolide on OVA-induced inflammatory cell 
recruitment in BAL fluid 
To determine the effects of andrographolide on the OVA-induced airway 
inflammation, BAL fluid was collected 24 hours after the last OVA or saline 
aerosol challenge, and total and differential cell counts were performed. In saline-
challenged mice, almost all BAL fluid cells were macrophages. OVA inhalation 
significantly (P < 0.05) increased total cell, eosinophil, lymphocyte, and 
neutrophil counts as compared with saline control (Figure 5.1). DMSO (2%) as 
vehicle did not show any inhibitory effects on BAL fluid cell counts in mice 
challenged with OVA (Figure 5.2). Our experience in using lower percentage of 
DMSO resulted in the precipitation of andrographolide and subsequent high 
variability in experimental endpoint. Andrographolide (0.1, 0.5 and 1 mg/kg) 
substantially decreased the total cell and eosinophil counts in BAL fluid in a dose-
dependent manner as compared with the DMSO vehicle control (Figure 5.2). 
Andrographolide at high dose (1 mg/kg) also reduced macrophage, lymphocyte, 
and neutrophil counts (Figure 5.2). We have used 5 mg/kg andrographolide in our 
preliminary study. Nevertheless, the inhibitory effects observed were no greater 
than 1 mg/kg andrographolide. As such, the highest dose used in the present study 
























Figure 5.1 Differential cell counts in BAL fluid. Inflammatory cell counts in BAL 
fluid obtained from sensitized mice 24 hours after the last saline aerosol or 10 
mg/ml OVA aerosol challenge (saline, n = 6; OVA, n = 7). Differential cell 
counts were performed on a minimum of 500 cells to identify eosinophil (Eos), 
macrophage (Mac), neutrophil (Neu), and lymphocyte (Lym). *Significant 
















































Figure 5.2 Effects of andrographolide on BAL fluid cell infiltration. 
Andrographolide reduced OVA-induced inflammatory cell counts in BAL fluid 
from sensitized mice 24 hours after the last 10 mg/ml OVA aerosol challenge 
(DMSO, n = 7; 0.1 mg/kg, n = 7; 0.5 mg/kg, n = 10; 1 mg/kg, n = 9). Differential 
cell counts were performed on a minimum of 500 cells to identify eosinophil 
(Eos), macrophage (Mac), neutrophil (Neu), and lymphocyte (Lym). *Significant 






































To further investigate if this inhibition of inflammatory cell migration into airway 
is due to the non-specific cytotoxic effects of andrographolide, we tested the 
population of peripheral blood leukocytes in mice. Flow cytometric analysis 
revealed that peripheral blood leukocytes from saline-challenged, OVA-
challenged, vehicle control, and andrographolide-treated mice had similar 
percentages of CD3+, CD4+, CD8+ T cells, B cells (B220), and NK cells (NK 1.1) 
(Figure 5.3). Hence, these results clearly demonstrate that andrographolide 
inhibits the recruitment of inflammatory cells during airway allergic inflammation.  
5.1.2. Effects of andrographolide on OVA-induced airway cell infiltration 
and mucus production 
To investigate effects of andrographolide on inflammatory cell infiltration 
into peribronchiolar and perivascular regions of the airway, as well as the mucus 
production, lung tissue was collected 24 hours after the last OVA or saline 
challenge. OVA aerosol challenge induced marked infiltration of inflammatory 
cells into the peribronchiolar and perivascular connective tissues as compared to 
saline challenge (Figure 5.4 A and B). Andrographolide (1 mg/kg) markedly 
diminished the eosinophil-rich leukocyte infiltration as compared to DMSO 
control (Figure 5.4 C, D, and I). On the other hand, OVA-challenged mice, but 
not saline-challenged mice, developed marked goblet cell hyperplasia and mucus 


















Figure 5.3 Effects of andrographolide on PBMC. Plasma was collected 24 hours 
after the last OVA or saline aerosol challenge. Expressions of (A) CD3, (B) CD4, 
(C) CD8, (D) NK1.1 and (E) B220 on PBMC were analyzed using FACS (n = 3 - 
5 mice per group). The dose of andrographolide was 1 mg/kg. Values shown are 



































































































































































Figure 5.4 A-D, I Effects of andrographolide on lung tissue inflammatory cell 
infiltration. Histologic examination of lung tissue eosinophilia (A, B, C, and D, 
magnification ×200) 24 hours after the last challenge of saline aerosol (A), OVA 
aerosol (B), OVA aerosol plus DMSO (C), or OVA aerosol plus 1 mg/kg 
andrographolide (D). Quantitative analyses of inflammatory cell infiltration (I) in 
lung sections were performed as described in chapter 3. Scoring of inflammatory 
cells was performed in at least three different fields for each lung section. Mean 
scores were obtained from four animals. *Significant difference from DMSO 







































Figure 5.4 E-H, J Effects of andrographolide on mucus production. Histologic 
examination of lung mucus secretion (E, F, G, and H, magnification ×200) 24 
hours after the last challenge of saline aerosol (E), OVA aerosol (F), OVA aerosol 
plus DMSO (G), or OVA aerosol plus 1 mg/kg andrographolide (H). Quantitative 
analyses of mucus production (J) in lung sections were performed as described in 
chapter 3. Scoring of goblet cells was performed in at least three different fields 
for each lung section. Mean scores were obtained from four animals. *Significant 






















The OVA-induced mucus secretion was significantly reduced by andrographolide 
(1 mg/kg) when compared to the DMSO control (Figure 5.4 G, H, and J).  DMSO 
has no effects on both the inflammatory cell infiltration and mucus hypersecretion 
induced by OVA (Figure 5.4 C and G). 
5.1.3.  Effects of andrographolide on cytokine levels in BAL fluid  
To determine the inflammatory cytokine levels in the lung, BAL fluid 
levels of IL-4, IL-5, IL-13, eotaxin, and IFNγ were measured using ELISA. OVA 
challenge in sensitized mice substantially increased IL-4, IL-5, and IL-13 levels 
into BAL fluid as compared with saline control (Figure 5.5). OVA moderately 
increased BAL fluid eotaxin level (Figure 5.6). In contrast, IFNγ, the Th1 
cytokine, was slightly decreased in OVA-challenged mice (Figure 5.7). 
Andrographolide significantly (P < 0.05) decreased IL-4, IL-5, and IL-13 in a 
dose dependant manner (Figure 5.5). At 1 mg/kg, andrographolide significantly 
reduced eotaxin levels in BAL fluid as compared with DMSO control (Figure 5.6). 
Interestingly, andrographolide (1mg/kg) markedly up-regulated IFNγ levels 
(Figure 5.7), shifting the Th-2 dominant animal model to Th1 immune response. 
The change of cytokine profile in BAL fluid after the treatment of 
andrographolide indicates that this drug inhibits an OVA-specific Th2 response.  
5.1.4. Effects of andrographolide on serum Ig levels 
In order to evaluate whether andrographolide could modify an ongoing 
































Figure 5.5 Effects of andrographolide on Th2 cytokines in BAL fluid. BAL fluids 
were collected 24 hours after the last OVA or saline aerosol challenge. The saline 
group refers to mice which were sensitized with OVA and challenged with saline. 
The OVA group refers to asthmatic mice which were both sensitized and 
challenged with OVA. The DMSO group indicates asthmatic mice which were 
treated with the drug solvent, DMSO. The 0.1, 0.5, and 1 group indicates 
asthmatic mice which were treated with three different doses of andrographolide 
(0.1 = 0.1 mg/kg, 0.5 = 0.5 mg/kg, and 1 = 1 mg/kg). Levels of (A) IL-4, (B) IL-5, 
and (C) IL-13 were analyzed using ELISA (n = 6 - 9 mice per group). Values 






























































Figure 5.6 Effects of andrographolide on eotaxin level in BAL fluid. BAL fluids 
were collected 24 hours after the last OVA or saline aerosol challenge. The saline 
group refers to mice which were sensitized with OVA and challenged with saline. 
The OVA group refers to asthmatic mice which were both sensitized and 
challenged with OVA. The DMSO group indicates asthmatic mice which were 
treated with the drug solvent, DMSO. The 0.1, 0.5, and 1 group indicates 
asthmatic mice which were treated with three different doses of andrographolide 
(0.1 = 0.1 mg/kg, 0.5 = 0.5 mg/kg, and 1 = 1 mg/kg). Level of eotaxin was 
analyzed using ELISA (n = 6 - 9 mice per group). Values shown are the mean ± 



































Figure 5.7 Effects of andrographolide on IFNγ level in BAL fluid. BAL fluids 
were collected 24 hours after the last OVA or saline aerosol challenge. The saline 
group refers to mice which were sensitized with OVA and challenged with saline. 
The OVA group refers to asthmatic mice which were both sensitized and 
challenged with OVA. The DMSO group indicates asthmatic mice which were 
treated with the drug solvent, DMSO. The 0.1, 0.5, and 1 group indicates 
asthmatic mice which were treated with three different doses of andrographolide 
(0.1 = 0.1 mg/kg, 0.5 = 0.5 mg/kg, and 1 = 1 mg/kg). Level of IFNγ was analyzed 
using ELISA (n = 6 - 9 mice per group). Values shown are the mean ± SEM. 




























serum levels of total IgE, OVA-specific IgE, OVA-specific IgG1, and OVA-
specific IgG2a were determined using ELISA. Substantial elevations in total IgE, 
OVA-specific IgE, and OVA-specific IgG1, but not in OVA-specific IgG2a, were 
observed in serum from OVA sensitized and challenged mice when compared to 
saline-challenged mice (Figure 5.8 and Figure 5.9). Surprisingly, andrographolide 
was able to significantly (P < 0.05) inhibit OVA-specific IgE levels, even at the 
lowest dose (0.1 mg/kg) (Figure 5.8), whereas lowered the level of total IgE and 
OVA-specific IgG1 in a dose dependent manner (Figure 5.8 and Figure 5.9). 
Andrographolide had no effects on the level of OVA-specific IgG2a (Figure 5.9), 
indicating a specific inhibition of Th2 response by andrographolide.  
5.1.5.  Effects of andrographolide on antigen recall in bronchial lymph node 
cells 
To assess whether andrographolide directly affect OVA-specific immune 
responses in lymphocytes, bronchial lymph nodes (3 - 4 nodes per mouse) were 
isolated and cultured, 24 hours after the last OVA or saline aerosol challenge, 
with or without andrographolide pre-treatment. Afterwards, single-cell 
preparations from lymph nodes were treated with OVA (200 µg/ml) for 72 hours, 
supernatant levels of IL-4, IL-5, and IFNγ were measured by ELISA.  The in vitro 
OVA-specific production of IL-4 and IL-5 was markedly higher in lymphocytes 
isolated from OVA-challenged mice than those from saline-challenged mice 














Figure 5.8 Effects of andrographolide on serum IgE production. Mouse serum was 
collected 24 hours after the last OVA or saline aerosol challenge. The saline group 
refers to mice which were sensitized with OVA and challenged with saline. The 
OVA group refers to asthmatic mice which were both sensitized and challenged 
with OVA. The DMSO group indicates asthmatic mice which were treated with 
the drug solvent, DMSO. The 0.1, 0.5, and 1 group indicates asthmatic mice 
which were treated with three different doses of andrographolide (0.1 = 0.1 mg/kg, 
0.5 = 0.5 mg/kg, and 1 = 1 mg/kg). The levels of (A) total IgE and (B) OVA-
specific IgE were analyzed using ELISA (n = 6 – 9 mice per group). Values 















































Figure 5.9 Effects of andrographolide on serum IgG production. Mouse serum was 
collected 24 hours after the last OVA or saline aerosol challenge. The saline group 
refers to mice which were sensitized with OVA and challenged with saline. The 
OVA group refers to asthmatic mice which were both sensitized and challenged 
with OVA. The DMSO group indicates asthmatic mice which were treated with 
the drug solvent, DMSO. The 0.1, 0.5, and 1 group indicates asthmatic mice 
which were treated with three different doses of andrographolide (0.1 = 0.1 mg/kg, 
0.5 = 0.5 mg/kg, and 1 = 1 mg/kg). The levels of (A) OVA-specific IgG1 and (B) 
OVA-specific IgG2a were analyzed using ELISA (n = 6 – 9 mice per group). 
Values shown are the mean ± SEM. *Significant difference from DMSO control, 












































Figure 5.10 Effects of andrographolide on OVA-specific response in vitro. 
Thoracic lymph nodes cells (n = 3 mice per group) were harvested from mice 24 
hours after the last OVA or saline aerosol challenge and cultured for 72 hours with 
OVA. The saline group refers to mice which were sensitized with OVA and 
challenged with saline. The OVA group refers to asthmatic mice which were both 
sensitized and challenged with OVA. The DMSO group indicates asthmatic mice 
which were treated with the drug solvent, DMSO. The 0.1, 0.5, and 1 group 
indicates asthmatic mice which were treated with three different doses of 
andrographolide (0.1 = 0.1 mg/kg, 0.5 = 0.5 mg/kg, and 1 = 1 mg/kg). The levels 
of (A) IL-4, (B) IL-5, and (C) IFNγ were analyzed using ELISA (n = 3 mice per 
group). Values shown are the mean ± SEM. *Significant difference from DMSO 
















































Andrographolide (1 mg/kg) pre-treatment significantly (P < 0.05) lowered the 
levels of both IL-4 and IL-5 (Figure 5.10 A and B). In addition, OVA-specific 
IFNγ production was found to be increased in mice treated with andrographolide 
(1 mg/kg) (Figure 5.10 C). Finally immune modulation by andrographolide in 
vivo was OVA-specific because concanavalin A (Con-A) induced production of 
IL-4, IL-5, and IFNγ in parallel cultures was not affected (Figure 5.11 A, B, and 
C). 
5.1.6.  Effects of andrographolide on lung mRNA expression of inflammatory 
markers 
To determine what other inflammatory mediators are affected by 
andrographolide, lung tissues were obtained 24 hours after the last OVA or saline 
challenge and processed to study mRNA levels of target mediators by RT-PCR. 
Recruitment of leukocytes from vessels into inflammatory sites are essential for 
the initiation of inflammatory responses to the development of asthma (Kelly et 
al., 2007). This recruitment of leukocytes, particularly eosinophils, is mediated by 
adhesion molecules (Jia et al., 1999; Medoff et al., 2008). OVA aerosol challenge 
moderately up-regulated the mRNA levels of adhesion molecules ICAM-1, 
VCAM-1, and E-selectin (Figure 5.12). Recent studies have revealed that a family 
of chitinase proteins including AMCase, Ym1, Ym2, and YKL-40, play critical 
roles in airway inflammation and remodeling (Moffatt and Cookson, 2008; Ober 























Figure 5.11 Effects of andrographolide on Con-A response in vitro. Thoracic 
lymph nodes cells (n = 3 mice per group) were harvested from mice 24 hours after 
the last OVA or saline aerosol challenge and cultured for 72 hours with Con-A.  
The levels of (A) IL-4, (B) IL-5, and (C) IFNγ were analyzed using ELISA (n = 3 
mice per group). Values shown are the mean ± SEM. *Significant difference from 











































































Figure 5.12 Effects of andrographolide on pulmonary mRNA expression of 
inflammatory markers. Lung tissues were collected 24 hours after the last OVA 
aerosol challenge. Total mRNA was extracted using TriZol reagent and the PCR 
products were separated in a 2% agarose gel visualized under ultraviolet light. β-
actin was used as an internal control. The experiments were repeated for three 
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All of these chitinase proteins were found to be elevated in our mouse asthma 
model (Figure 5.12).Mucus hypersecretion is the hallmark of asthama and 
Muc5ac is essential for mucin production (Zuhdi Alimam et al., 2000). TSLP, 
which is produced by epithelial cells, has been found to condition DC maturation 
and regulate Th2 responses in asthma (Liu et al., 2007; Soumelis et al., 2002). 
Nitric oxide (NO) is a mediator of airway and smooth muscle tone, which is 
synthesized by enzymes that have cytokine inducible form such as inducible nitric 
oxide synthase (iNOS) (Fischer et al., 2002). iNOS is up-regulated in the airways 
of asthmatic patients (Hamid et al., 1993). OVA challenge dramatically increased 
the expression of Muc5ac, TSLP, and iNOS (Figure 5.12). We found that pre-
treatment with andrographolide (10 mg/kg) moderately decreased levels of 
ICAM-1, VCAM-1, and dramatically reduced the level of E-selectin, which is 
consistent with the decreased levels of leukocytes in BAL fluid (Figure 5.12).  
Furthermore, andrographolide reduced gene expressions of inflammatory 
mediators such as Chitinases, Muc5ac, TSLP, iNOS in the allergic airway (Figure 
5.12).  
5.1.7.  Effects of andrographolide on OVA-induced AHR in mice  
To investigate the effect of andrographolide on AHR in asthmatic mice in 
response to increasing concentrations of methacholine, we measured both RI and 
Cdyn in mechanically ventilated mice with and without pretreatment of 
andrographolide. As compared to saline-challenged group, OVA-challenged mice 
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developed greater AHR which is typically reflected by high RI and low Cdyn 
(Figure 5.13 and Figure 5.14). Andrographolide (1 mg/kg) dramatically 
suppressed RI (Figure 5.13) and restored Cdyn (Figure 5.14) in OVA-challenged 
mice in response to methacholine as compared to DMSO control, suggesting that 
OVA-induced AHR was modified after the treatment of andrographolide. DMSO 
did not affect AHR in OVA-challenged mice (Figure 5.13 and Figure 5.14).   
5.1.8. Effects of andrographolide on TNF-α-induced NF-κB activation in 
A549 cells 
To explore anti-inflammatory mechanisms of andrographolide, we studied 
the effects of andrographolide on TNF-α induced NF-κB activation in A549 cells. 
A549 cells were pre-incubated with andrographolide (30 µM) for 4 hours and then 
exposed to TNF-α (10 ng/ml). Total proteins of cells were harvested at 0, 5, 15, 
and 30 min after the stimulation of TNF-α. TNF-α quickly induced the 
phosphorylation of IKKβ and IκBα within 5 min, leading to the following 
degradation of IκBα (Figure 5.15). Andrographolide completely inhibited the 
phosphorylation of IKKβ, markedly reduced the phosphorylation of IκBα, and 
delayed the following IκBα degradation as compared with control (Figure 5.15). 
As one of p65 kinases, IKKβ can phosphorylate p65 at Ser536 and enhance the 
transcriptional activity of p65 (Perkins, 2007). Andrographolide also decreased 





















Figure 5.13 Effects of andrographolide on airway resistance. Airway 
responsiveness of mechanically ventilated mice in response to intravenous 
methacholine was measured 24 hours after the last saline aerosol or OVA aerosol 
with pretreatment of either DMSO or 1 mg/kg andrographolide. AHR is expressed 
as percentage change from the baseline level of RI (n = 5). *Significant difference 














































Figure 5.14 Effects of andrographolide on airway dynamic compliance. Airway 
responsiveness of mechanically ventilated mice in response to intravenous 
methacholine was measured 24 hours after the last saline aerosol or OVA aerosol 
with pretreatment of either DMSO or 1 mg/kg andrographolide. AHR is expressed 
as percentage change from the baseline level of Cdyn (n = 5). *Significant 





















































Figure 5.15 Effects of andrographolide on TNF-α induced NF-κB activation in 
A549 cells. A549 cells were incubated with or without andrographolide (30 µM) 
for 4 hours and then stimulated with TNF-α (10 ng/ml) for the indicated times. 
Total proteins of cells were isolated and analyzed by Western blotting with the 
indicated antibodies. β-actin was used as an internal control. The experiments 
















Because IκBα degradation is required for the activation of NF-κB canonical 
pathway, we further tested the translocation of p65 and p65 DNA-binding activity 
using nuclear proteins isolated from the cells, 30 min after the stimulation of 
TNF-α. TNF-α induced the accumulation of p65 on nucleus (Figure 5.16) and 
increased the p65 DNA-binding activity (Figure 5.17). Andrographolide reduced 
the translocation of p65 and DNA-binding activity as compared with control 
(Figure 5.16 and Figure 5.17), suggesting andrographolide reduces the activity of 
the NF-κB pathway via inhibiting the phosphorylation of IKKβ.  
5.1.9. Effect of andrographolide on NF-κB DNA-binding activity in vivo 
To study if andrographolide modulates NF-κB activity in the asthma model, 
lung tissues were obtained 24 hours after the last OVA or saline challenge and a 
TransAM assay was performed on the nuclear proteins to measure NF-κB DNA-
binding activity. OVA challenge markedly increased p65 DNA-binding activity in 
the lung tissue as compared with saline control, indicating enhanced NF-κB 
activity in asthma model (Figure 5.18). Andrographolide was able to significantly 
(P < 0.05) reduce DNA-binding activity when compared with DMSO vehicle 
control, suggesting andrographolide could decrease NF-κB activity and block 
inflammatory responses in asthma (Figure 5.18). DMSO had no effects on DNA-
binding activity as compared with OVA-challenged group. The NF-κB signaling 
pathway is essential in both innate and adaptive immune responses and in the 


















Figure 5.16 Effects of andrographolide on TNF-α induced translocation of p65 in 
A549 cells. A549 cells were incubated with or without andrographolide (30 µM) 
for 4 hours and then stimulated with TNF-α (10 ng/ml) for 30 min. Nuclear 
proteins of cells were isolated and analyzed by Western Blotting with p65 
antibody. β-actin was used as an internal control. The experiments were repeated 




































Figure 5.17 Effects of andrographolide on TNF-α-induced p65 DNA-binding 
activity in A549 cells. A549 cells were incubated with or without andrographolide 
(30 µM) for 4 hours and then stimulated with TNF-α (10 ng/ml) for 30 min. 
Nuclear proteins of cells were isolated and analyzed by TransAM assay. Values 
shown are the mean ± SEM of three separate experiments. *Significant difference 
















































Figure 5.18 Effects of andrographolide on p65 DNA-binding activity in lung 
tissue. Lung tissues were collected 24 hours after the last OVA or saline aerosol 
challenge pretreated with either DMSO or andrographolide (1mg/kg). Nuclear 
protein was isolated and DNA-binding activity was measured by TransAM assay. 
Values shown are the mean ± SEM of three separate experiments. *Significant 



































Disruption of p65 or IKKβ genes causes embryonic lethality in mice due to severe 
liver degeneration (Beg et al., 1995; Li et al., 1999b). To further investigate the 
toxicity of andrographolide on the function of liver due to the inhibition of IKKβ 
activity, we measured the activities of serum ALT and AST, indicators of 
hepatocellular injury, using a kinetic spectrophotometric assay. Andrographolide 
did affect the activities of both ALT and AST (Figure 5.19).  
5.1.10.   Effects of andrographolide on activities of MAP kinases in vitro 
 Previously, several studies indicated andrographolide might exert its anti-
inflammatory effects by inhibiting the ERK MAP kinase pathway (Liang et al., 
2008; Qin et al., 2006). To investigate the possible mechanisms of 
andrographolide in ERK pathway, we also tested if andrographolide affects TNF-
α-induced the phosphorylation of MEK1/2 and ERK1/2 in the epithelial cells with 
the pretreatment of DMSO or andrographolide. Interestingly, andrographolide 
markedly inhibited TNF-α-induced the phosphorylation of MEK1/2 and slightly 
reduced the phosphorylation of ERK1/2 in epithelial cells compared with control 
(Figure 5.20). These results suggest andrographolide also can affect the MAP 
kinas pathway, although whether the inhibition of MEK and ERK by 
andrographolide is related to the inhibition of the phosphorylation of IKKβ still 



























Figure 5.19 Effects of andrographolide on the activities of serum ALT and AST. 
Mouse serum was collected 24 hours after the last OVA or saline aerosol 
challenge pretreated with either DMSO or andrographolide (1 mg/kg). The 
activities of (A) ALT and (B) AST were analyzed using a kinetic 
spectrophotometric assay (n = 5 – 6 mice per group). Values shown are the mean 




























































Figure 5.20 Effects of andrographolide on TNF-α-induced MEK and ERK 
activation in A549 cells. A549 cells were incubated with or without 
andrographolide (30 µM) for 4 hours and then stimulated with TNF-α (10 ng/ml) 
for the indicated times. Total proteins of cells were isolated and analyzed by 
Western blotting with the indicated antibodies. β-actin was used as an internal 

















5.2.   Discusssion 
The medicinal plant andrographis paniculata has been widely used for a 
variety of diseases in Asia for a long time (Negi et al., 2007). The diterpene 
compound andrographolide is the major component in this plant and has been 
shown to possess anti-inflammatory activities (Panossian et al., 2000; Wang et al., 
2004; Wang et al., 2007). Andrographolide has been shown to suppress 
complement-5a induced chemotactic cell migration (Tsai et al., 2004), reduce the 
production of TNF-α and IL-12 in LPS-stimulated murine peritoneal macrophages 
(Qin et al., 2006), and inhibit partially the IL-2 production induced by Con-A in 
murine T cells (Burgos et al., 2005), probably via the inhibition of extracellular 
signal-regulated kinase1/2 (ERK)1/2. Andrographolide may also prevent reactive 
oxygen species in human neutrophils via interference of the protein kinase C-
dependent pathway (Shen et al., 2002). Moreover, andrographolide is able to 
interfere with T cell proliferation and cytokine release in response to allogenic 
stimulation, through the blockade of dendritic cell maturation and their ability to 
present antigens, suggesting an immuno-modulatory activity of andrographolide 
(Iruretagoyena et al., 2005). Although there are numerous reports on the 
pharmacological activities of andrographolide, the detailed molecular mechanisms 
remain unclear. Recently, andrographolide has been found to attenuate 
inflammation by inhibiting the NF-κB pathway via covalent modification of 
reduced cys62 of the p50, one subunit of NF-κB (Wang et al., 2007; Xia et al., 
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2004). Because a variety of NF-κB-dependent genes, such as iNOS, VCAM-1, 
ICAM-1, TNF-α, and IL-6, have found to be modulated by andrographolide, it is 
highly likely that andrographolide may exert its anti-inflammatory effects via 
modulating NF-κB pathway.  
NF-κB activity is up-regulated in allergic airway inflammation both in human 
and in animal models of asthma (Broide et al., 2005; Donovan et al., 1999; 
Gagliardo et al., 2003; Hart et al., 1998; Poynter et al., 2004). Various therapeutic 
strategies targeted at the NF-κB signaling pathway such as NF-κB specific decoy 
oligonucleotide (Desmet et al., 2004), p65-specific antisense oligonucleotide 
(Choi et al., 2004), and IKK-2 selective small molecule inhibitors (Birrell et al., 
2005) have demonstrated beneficial effects in experimental asthma models. 
Therefore, we investigated the potential anti-inflammatory effects of 
andrographolide in an asthma mouse model and its molecular mechanisms of 
action. 
Asthma is a Th2-polarized chronic inflammatory disease (Meyer et al., 2008). 
Asthmatic patients are genetically predisposed toward the differentiation of  naïve 
T cells into Th2 cells and away from the Th1 cells (Mazzarella et al., 2000). 
CD4+ Th2 cells play an essential role in the pathophysiology of the allergic 
airway inflammation (Herrick and Bottomly, 2003). Th2 cytokines, including IL-4, 
IL-5, and IL-13, can be produced by various resident cells such as bronchial 
epithelial cells, mast cells, and alveolar macrophages, as well as by infiltrated 
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inflammatory cells such as lymphocytes and esosinophils. IFNγ is the main Th1 
cytokine and its production is inhibited by Th2 cytokines such as IL-4 and IL-13 
(Mazzarella et al., 2000). NF-κB is a critical transcription factor for Th2 cell 
differentiation, via regulation of GATA-3, which is uniquely expressed in Th2 
cells (Das et al., 2001). Moreover, it has been shown that NF-κB is necessary for 
the induction of IL-13 upon the cross-linking FcεRΙ in human mast cells (Lorentz 
et al., 2003). Our data show that andrographolide dramatically reduced the levels 
of IL-4, IL-5, and IL-13, but slightly increased IFNγ levels in BAL fluid from 
OVA-challenged mice, in a dose-dependent manner. These findings are consistent 
with the opposing profile of Th1/Th2 paradigm in asthma. Several studies, on the 
inhibition of  the NF-κB function in OVA-challenged mice using conditional 
knockout of IKKβ transgenic IκBα mutant expression selectively in airway 
epithelium (Broide et al., 2005; Poynter et al., 2004), or aerosol administration of 
NF-κB decoy oligonucleotide (Desmet et al., 2004),  showed a similar inhibitory 
pattern of cytokine profile as our presenting findings, suggesting that 
andrographolide may exert its anti-inflammatory effects via inhibition of the NF-
κB signaling pathway. Antigen receptor activation in T and B cells and in mast 
cells has been shown to culminate in NF-κB activation (Li et al., 2004; Peng et al., 
2005; Weil and Israel, 2004), and andrographolide may modulate NF-κB mediated 
cytokine production in these inflammatory cells. In addition, airway smooth 
muscle is another source of proinflammatory cytokines and may also promote 
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recruitment, activation, and migration of inflammatory cells during the airway 
inflammation (Howarth et al., 2004; Tliba et al., 2008). Repression of NF-κB 
signaling pathway has been shown to block IL-13-induced eotaxin production in 
cultured human airway smooth muscle cells (Birrell et al., 2005). As such, the 
observed reduction of IL-4, IL-5, and IL-13 levels in BAL fluid from 
andrograhpolide treated mice may be due to inhibition of NF-κB activation in 
those inflammatory and airway resident cells.  
The recruitment of inflammatory cells, particularly eosinophils, into the 
airways is one of the hallmarks of asthma (Kelly et al., 2007; Rothenberg and 
Hogan, 2006).  Our findings showed that andrographolide prevented the 
infiltration of inflammatory cells, such as eosinophils and lymphocytes, into the 
airways, in a dose dependent manner, as shown by a significant drop in total cell 
counts and differential cell counts in BAL fluid. In agreement with BAL fluid cell 
count data, there was also a reduction in the infiltration of inflammatory cells into 
peribronchiolar and perivascular tissues shown by histological examinations. The 
recruitment of inflammatory cells from circulation into the airways is a dynamic 
and multistep process which includes rolling, adhesion, and transmigration (Kelly 
et al., 2007; Ley et al., 2007; Medoff et al., 2008). Rolling is mediated by selectins, 
which interact with glycoprotein ligands. Chemokines are believed to play a key 
role in triggering adhesion of inflammatory cells. They activate integrins 
expressed on inflammatory cells, which bind to adhesion molecules, such as 
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ICAM-1 and VCAM-1, expressed on endothelial cells, leading to the adhesion of 
inflammatory cells. The mechanisms of migration still remain unclear. A wide 
variety of proteins, including CD99 and junctional adhesion molecules, have been 
involved in this migration process. In asthma, trafficking of inflammatory cells 
into airways is orchestrated by Th2 cytokines, including IL-4, IL-5, and IL-13, 
eotaxins, and adhesion molecules, such as VCAM-1, ICAM-1, and E-selectin (Jia 
et al., 1999; Kelly et al., 2007; Ono et al., 2003; Rothenberg and Hogan, 2006). 
IL-4 and IL-13 can induce the expression of VCAM-1 in endothelial cells, 
facilitating the recruitment of inflammatory cells in asthma (Bochner et al., 1995). 
IL-13 is also a potent stimulator of chemokines, including eotaxin-1, eotaxin-2, 
and MCP-1, in the airways (Li et al., 1999a; Zhu et al., 2002).  We demonstrated 
that andrographolide slightly down-regulated the expression of VCAM-1, ICAM-1, 
remarkedly decreased the level of E-selectin in OVA-challenged lungs, and 
significantly reduced eotaxin-1 levels in BAL fluid. These results are likely to be 
due to an induced inhibition of NF-κB pathway by andrographolide, as the gene 
expression of VCAM-1, ICAM-1, E-selectin, and eotaxins, are all regulated by the 
NF-κB pathway (Kumar et al., 2004).  Taken together, the observed reduction of 
inflammatory infiltration in airways may be a composite effect of the reduction of 
IL-13 and the decrease in the expression of eotaxin and adhesion molecules, 
secondary to the blocking of NF-κB pathway by the treatment of andrographolide.   
 144 
Mucus hypersecretion, including excessive mucus secretion, goblet cell 
hyperplasia, and submucosal gland hypertrophy, is a consistent feature in asthma 
(Morcillo and Cortijo, 2006).  Mucus hypersecretion also contributes to airflow 
limitation and AHR, and are associated with high morbidity and mortality in 
uncontrollable asthma patients (Morcillo and Cortijo, 2006).  We found that 
andrographolide significantly reduced goblet cell hyperplasia and excessive 
mucus secretion shown by histological examinations, as compared with DMSO 
control. There is cumulative evidence to support the pivotal role of IL-13 in the 
mucus hypersecretion observed in asthma (Wills-Karp, 2004). Blockade of IL-13 
alone has been shown to prevent the mucus hypersecretion in asthma mouse 
model (Wills-Karp et al., 1998; Zhu et al., 1999). Components of IL-13 signaling 
pathway such as STAT-6, also have been shown to be involved in the production 
of mucus (Gavett et al., 1997; Kuperman et al., 1998). The role of IL-5 in the 
mucus hypersecretion remains unclear. It has also been proposed that the 
expression of IL-5 in the airway alone is sufficient to  induce CD4(+) T cell-
dependent goblet cell metaplasia in a study of a pulmonary IL-5 transgenic mouse 
model (Justice et al., 2002). However, IL-4- and IL-13-deficient but not IL-5-
deficient mice were protected from airway mucin changes after chronic allergen 
exposure (Leigh et al., 2004). NF-κB pathway also plays an important role in the 
mucus hypersecretion and selective ablation of NF-κB function in airway 
epithelium inhibited OVA-induced mucus production in mice (Broide et al., 2005; 
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Desmet et al., 2004; Poynter et al., 2004). Interestingly, the Muc5ac gene, which 
is implicated in the production of gel-forming mucins in the airway, is regulated 
by a IKKβ dependent mechanism in epithelial cells following the stimulation with 
TNF-α (Lora et al., 2005). We also observed a drastic drop in the level of Muc5ac 
mRNA by the treatment of andrographolide in OVA-challenged asthma mouse. 
Therefore, the dramatic decrease in mucus production of airway in the 
andrographolide-treated mice may be attributed to a substantial drop in Th2 
cytokines, particularly IL-13. Moreover, the inhibition of NF-κB pathway by 
andrographolide may affect mucus production via an indirect way through 
regulation of the Muc5ac gene.  
Elevated serum IgE and IgG1 are the hallmarks of a Th2 immune response 
in mice (Avila, 2007; Okahata et al., 1990; Vance et al., 2004). Our data showed 
that serum levels of total IgE, OVA-IgE and OVA-IgG1 were greatly decreased by 
andrographolide, whereas no significant inhibition was observed in OVA-IgG2a, 
an indicator of Th1 response. NF-κB pathway has been found to be involved in the 
differentiation and maturation of B lymphocytes (Matthias and Rolink, 2005). 
Selective p50- or p52- deficient mice have exhibit malfunction of B lymphocytes 
(Cariappa et al., 2000; Franzoso et al., 1997). B lymphocytes produce OVA-
specific IgE or IgG after undergoing Ig class switching. This process in asthma 
requires two signals, one of which is specific antigen and cytokines such as IL-4 
and IL-13, by IL-4 receptor α chain via STAT-6 pathway (Emson et al., 1998; 
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Wills-Karp, 2004). The second signal is the interaction between CD40 on B cells 
and CD40L on activated Th cells. The   biological activities of IgE are mediated 
by its interaction with FcεRΙ on mast cells and basophils (Kawakami and Galli, 
2002). Crossing linking of IgE and FcεRΙ lead to degranulation of mast cells and 
release of histamines, leukotrienes, and prostaglandins, initiating the multiple 
signaling cascades in asthma . These mediators also act on smooth muscle cells, 
causing acute bronchoconstriction which initiate the early-phase reactions of 
asthma.  It has been shown that NF-κB may also be involved in the IgE-mediated 
mast cell activation (Lorentz et al., 2003; Peng et al., 2005). Therefore, the 
observed reduction in serum total IgE, OVA-IgE, and OVA-IgG1 in our asthma 
model by the treatment of andrographolide may be due to its inhibitory effects on 
B cell activation, Th2 cytokine production from inflammatory cells via NF-κB 
pathway.   
Chitin is a polymer of N-acetylglucosamine and is the one of the 
components of the cell walls of fungi and exoskeletal elements worms and 
arthropods, but except mammals (Elias et al., 2005).  Chitinases are a group of 
enzymes that break down chitin structures in organisms. Previously, chitinases 
were only considered as part of innate immune response of host againt a chitin-
containing pathogen. Recently, a family of chitinase proteins including AMCase, 
Ym1, Ym2, YKL-40 has been found to be dramatically increased in allergic 
airway inflammation and to be involved in the pathophysiology of asthma (Chupp 
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et al., 2007; Elias et al., 2005; Moffatt and Cookson, 2008; Webb et al., 2001; 
Zhao et al., 2005; Zhu et al., 2004). One study has shown that AMCase is induced 
in a IL-13-dependent manner in epithelium and macrophages in an asthma mouse 
model and is increased in asthma patients as compared with normal controls (Zhu 
et al., 2004).  When given intratracheally, IL-13 increased Ym1 and Ym2 levels in 
BAL fluid from mice (Webb et al., 2001). YKL-40, also called chitinase-3-like-1, 
is elevated in the serum of asthma patients and is correlated with severity of 
asthma (Chupp et al., 2007). Moreover, the gene that encodes YKL-40 is 
considered a susceptibility gene for asthma by a large population study (Ober et 
al., 2008). Although the mechanisms of chitinases in asthma remain unclear, they 
may trigger immune responses upon antigen challenge, act directly as a kind of 
chemotactic agents, regulate tissue inflammation and remodeling, or work just as 
a biomarker for asthma (Elias et al., 2005). Our data have showed that 
andrographolide moderately inhibited the expression of AMCase and Ym-1, but 
greatly suppressed Ym-2 and YKL-40 in the OVA-challenged lungs as compared 
with vehicle control. The reduction of chitinases, especially Ym-2 and YKL-40, 
by the treatment of andrographolide may be a result of decreased level of IL-13 in 
the airways. Furthermore, AMCase contributes to the Th2-polarized inflammation 
(Zhu et al., 2004). It also has been shown that Ym-1 protein is a potent 
chemotactic agent for eosinophils and CD4+ T cells (Owhashi et al., 2000). The 
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decreased chitinases may further lead to diminished infiltration of inflammatory 
cells in the lung.  
NO is a ubiquitous gaseous molecule that regulates airway and vascular 
smooth muscle tone. There has been shown that the increased level of NO is 
associated with the severity of asthma and may reflect allergic inflammation in the 
airways (Kharitonov et al., 1995; Massaro et al., 1995). Furthermore, inhaled 
corticosteroids can dramatically reduce the level of exhaled NO in asthma patients 
(Kharitonov et al., 1996a; Kharitonov et al., 1996b; van Rensen et al., 1999). NO 
is synthesized by three different oxide synthases, of which the most important one 
in the airway is iNOS. iNOS is induced by proinflammatory cytokines in a variety 
of cells including macrophages and epithelium. The iNOS was found to be 
elevated in the airway epithelium and macrophages in asthma patients (Hamid et 
al., 1993). The increased level of iNOS may be due to the effects of 
proinflammatory cytokines, oxidants, and other inflammatory mediators. Although 
some studies have supported the role of NO and iNOS in asthma, the mechanisms 
of NO and iNOS remain controversial and unclear (Di Maria et al., 2000; Fischer 
et al., 2002; Ricciardolo, 2003).  Cumulative evidence has proved that the gene of 
iNOS is regulated by the NF-κB pathway (Pahl, 1999). In addition, IL-13 was 
found to induce iNOS derived NO in normal human bronchial epithelial cells 
(Chibana et al., 2008; Suresh et al., 2007). Consistent with previous data, level of 
iNOS in lung tissue of our asthma model was elevated. The reduced level of iNOS 
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by the treatment of andrographolide may be due to the inhibition of NF-κB 
pathway and reduced IL-13 level in airways.  
TSLP is an epithelial cell-derived cytokine and play a key role in the 
initiation and maintenance of asthma in a dendritic cell- and mast cell-mediated 
Th2 immune response (Allakhverdi et al., 2007; Liu, 2007; Rochman et al., 2007). 
The  expression  of TSLP  is  increased  in  the asthmatic  airways  and  correlates  
with  the  severity  of  asthma  (Ying et al., 2005). Furthermore, it has been shown 
that TSLP is regulated by a NF-κB-dependent manner in human airway epithelia 
cells and the promoter of the mouse TSLP gene contains an orthologous NF-κB 
binding site (Lee and Ziegler, 2007). Our data have shown that andrographolide 
remarkedly inhibited the expression of TSLP in the lung tissue of asthmatic mouse 
as compared with vehicle control. This reduction of TSLP level may be due to the 
inhibition of NF-κB pathway by andrographolide and further contribute to the 
decreased Th2 cytokines production in airways.  
It is believed that inflammatory mediators released during the allergic 
inflammation play a critical role in AHR development (Cohn et al., 2004; 
Fernandes et al., 2003). We report here that andrographolide significantly 
inhibited OVA-induced AHR to increasing concentrations of methacholine. IL-5 
is responsible for the differentiation, maturation, and activation of eosinophils, 
and plays a critical role in AHR by mobilizing and activating esoinophils, leading 
to the release of pro-inflammatory products such as major basic protein and 
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cysteinyl-leukotrienes, which are closely associated with AHR (Rothenberg and 
Hogan, 2006). Blockade of IL-4 receptor has been shown to inhibit the allergen-
induced AHR in mice and inhaled IL-4 induced AHR in response to methacholine 
in a human placebo-controlled study, indicating that IL-4 can increase AHR in 
asthma (Gavett et al., 1997; Shi et al., 1998).  In addition, IL-13 has been shown 
to induce AHR in mouse asthma models in which cysteinyl-leukotrienes have 
been implicated in AHR (Vargaftig and Singer, 2003; Wills-Karp, 2004). 
Moreover, IgE-mediated mast cell activation may contribute to AHR by 
producing a wide array of inflammatory mediators and cytokines (Lorentz et al., 
2003). Thus, the observed reduction of AHR may be associated with reduction in 
Th2 cytokine production, tissue eosinophilia, and serum IgE level by 
andrographolide. 
We found that treatment with andrographolide inhibited OVA-induced p65 
DNA-binding activity in the lung tissue, which is consistent with anti-
inflammatory effects of andrographolide in the asthma model. To further study 
how andrographolide interferes with NF-κB pathway, we investigated the effects 
of andrographolide on TNF-α-induced NF-κB activation in A549 human epithelial 
cells. We found that andrographolide inhibited TNF-α induced phosphorylation of 
IKKβ, leading to the decreased phosphorylation of IκBα, delayed degradation of 
IκBα, reduced translocation of p65, diminished DNA-binding activity of p65. 
Activation of IKK complex depends on ubiquitination of NEMO, phosphorylation 
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of IKKβ and IKKα, and IKK multimerization in response to stimuli such as TNF-
α, in the canonical pathway (Hacker and Karin, 2006).  The activated IKK 
complex then phosphorylates IκBα, causing the ubiquitination and following 
degradation of IκBα. Following the degradation of IκBα, NF-κB subunit p65 
translocates into the nucleus and activate the expression of targeted genes 
(Perkins, 2007). Therefore, andrographolide may exert its anti-inflammatory 
effects via inhibition of the phosphorylation of IKKβ. IKK complex subunits also 
have various substrates. Activation of IKKβ can lead to the phosphorylation of 
p65 at Ser536 and its nuclear translocation, enhancing p65 transactivation 
functions by promoting interactions with coactivator proteins, such as p300 and 
CBP (Perkins, 2007; Sizemore et al., 2002). We postulate that the reduction in the 
phosphorylation of p65 at Ser536 after the treatment of andrographolide in 
epithelial cells may be due to the inhibition of the phosphorylation of IKKβ.  
Because previously there are many reports about the effects of 
andrographolide on the ERK MAP kinase pathway, we also tested TNF-α-induced 
phosphorylation of MEK1/2 and ERK1/2 in the epithelial cells with the pre-
treatment of DMSO or andrographolide. Interestingly, we found the reduced 
phosphorylation of MEK1/2 and its downstream ERK1/2 after the treatment of 
andrographolide in epithelial cells. It has been shown that there are also links 
between IKKβ and the MAP kinase pathway (Perkins, 2007). In resting cells, the 
MEK kinase (tumor progression locus 2 [TPL2]), which is required for the TNF-α 
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induced MEK and ERK activation (Eliopoulos et al., 2003), forms a complex with 
one NF-κB subunit p105, which is the precursor of p50 (Belich et al., 1999; 
Waterfield et al., 2003). The activation of IKKβ may induce the proteolysis of 
p105 or phosphorylaiton of TPL2 at Thr290, which in turn leads to the release of 
bound TPL2 from the complex, causing the activation of MEK and ERK pathway 
(Beinke et al., 2004; Cho et al., 2005; Cho and Tsichlis, 2005; Waterfield et al., 
2004). Therefore, the reduced phosphorylation of MEK1/2 and ERK1/2 may be 
due to the inhibited IKKβ activity or direct inhibition of phosphorylation of 
MEK1/2 by the andrographolide. 
Allergic airway inflammation is a complex disorder, involving a wide array 
of inflammatory cells and mediators. We report that andrographolide effectively 
inhibited OVA-induced Th2 cytokines and eotaxin production, pulmonary 
infiltration of inflammatory cells, serum IgE and IgG1 synthesis, mucus 
hypersecretion, and AHR in a mouse asthma model, via the inhibition of NF-κB 
pathway. These finding support that andrographolide, as an active ingredient of 
herb medicinal, may have potential in the treatment of asthma. 
Our data have shown the efficacy of andrographolide in the asthma mouse 
model. However, there are still some questions regarding the potential use of 
andrographolide in asthma patients. First, the toxicity of andrographolide should 
be tested in asthma patients. Although andrographis paniculata has been used as a 
herbal medicine for a long time in Asia and Scandinavia, the pharmacokinetics of 
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andrographolide in asthma patients remains unknown. Second, the effects of 
andrographolide, combined with inhaled corticosteroids or long-acting β2 agonist, 
in asthma mouse model remain unclear. Third, we will precede the 
andrographolide to clinical trials for asthma patients, if the toxicity of drug and 
proper dose of drug in human patients are confirmed by preliminary experiments. 
The efficacy of andrographolide in different genotype or phenotype of the 
particular asthma subtype might be assessed in the future. In brief, although 
andrographolide is a promising herbal drug for asthma patients, there are still 
more questions than answers about the toxicity, efficacy, and mechanisms of 







































The NF-κB family is essential in coordinating both innate and adaptive 
immunity and is involved in the regulation of a broad array of genes in response to 
diverse stimuli. This study demonstrates the potential anti-inflammatory effects of 
a GSK-3β inhibitor, TDZD-8, and a herbal medicinal, andrographolide in a mouse 
asthma model and elucidates their mechanisms of action in the regulation of NF-
κB pathway. 
This study demonstrates that TDZD-8 is effective in blocking 
phosphorylation of p65 at Ser536 in an asthma model and in TNF-α-stimulated 
normal human bronchial epithelial cells. TDZD-8 inhibited ovalbumin-induced 
total cell counts, eosinophil counts, Th2 cytokines and eotaxin production, serum 
OVA-IgE, pulmonary infiltration of inflammatory cells, mucus hypersecretion in 
lungs, AHR to methacholine in an asthma mouse model, probably via the 
inhibition of the phosphorylation of NF-κB subunit p65. 
Accordingly, we examined anti-inflammatory effects of another potential 
NF-κB inhibitor, in an asthma mouse model. Andrographolide, given 
intraperitoneally, markedly inhibited OVA-induced airway and lung tissue 
infiltration of inflammatory cells, Th2 cytokines and chemokines release, serum 
total and specific IgE and IgG1, airway mucus production, expression of the 
inflammatory molecules, and AHR in the asthma model. Further experiments for 
the effects of andrographolide in epithelial cells revealed that andrographolide 
reduced the TNF-α induced phosphorylation of IKKβ, causing the decreased p65 
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DNA-binding activity and diminished phosphorylation of p65. These results 
suggest that specific regulation of the phosphorylation of key molecules in the 
NF-κB pathway may provide a significant advance in the treatment of asthma. 
This study indicates the regulation of posttranscriptional activity in the NF-
κB pathway such as phosphorylation of IKKβ and p65, by TDZD-8 and 
andrographolide exhibits anti-inflammatory effects in asthma model as compared 
with direct inhibition of IKKβ kinase activity or expression of p65. Taken together, 
the present findings implicate that appropriate and specific inhibition of signaling 
molecules that regulate the NF-κB pathway may have therapeutic potential for the 
treatment of allergic airway inflammation, without compromising immunity and 
cell survival, thereby avoiding potential side effects.  
In the future, we may need to do more research about the mechanisms and 
clinical efficacies of these two drugs. Because phosphorylation of the components 
of NF-κB pathway is a dynamic process, more studies need to be done to 
investigate the precise regulation mediated by these two drugs. Combination of 
any one of these drugs with inhaled steroids may reveal their synergistic effects in 
asthma. Understanding multiple mechanisms of these two drugs and their effects 
in steroid-resistant asthma might show their unique roles in refractory asthma 
besides anti-inflammatory effects. Finally, clinical trials are needed to confirm the 
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List of Reagents and Solutions 
Sensitization solution for mouse asthmatic model 
OVA (grade Ⅴ)        20 µg 
Al(OH)3         4 mg 
Saline          0.1 ml 
 
Challenge solution (15 ml) 
OVA (grade Ⅴ)        0.15 g 
Saline          15 ml 
 
Modified Wright’s staining (Liu’s staining) 
Liu A  Eosin Y       0.18 g 
  Methylene blue      0.05 g 
  Methanol       100 ml 
Liu B  Methylene blue      0.7 g 
  Azur Ⅰ       0.6g 
  Na2HPO4 ·12H2O      12.6 g 
  KH2PO4       6.25 g 
  H2O        500ml 
 
Red cell lysis buffer for BAL fluid cell counts (2 ml) 
NH4Cl          0.0175 g 
H2O          2 ml 
 
Diluent buffer for BAL fluid cell counts (4 ml) 
RPMI          4 ml 
BSA          0.04 g 
 
Sample lysis buffer (Western Blotting) 
Tris-HCl pH7.4        75 mM 
NaCl          150 mM 
Triton X-100         1% 
Glycerol         10% 
Protease inhibitor cocktail       1X 
Dilution 
NaF          20 mM 
 
10% APS (fresh preparing) 
APS          20 mg 
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H2O          200 µl 
 
5X Sample Buffer 
3 M Tris-HCl pH 6.8        312.5 mM 
Glycerol         50% 
2-mercaptoethanol        25% 
SDS          10% 
1% Bromophenol blue       0.0625% 
 
10% SDS (100 ml) 
Sodium dodecyl suphate       10 g 
H2O          100 ml  
 
Running gel (15 ml for 2 gels) 
1.5 M Tris-HCl pH8.8       3.73 ml 
H2O          5.96 ml 
30% Acrylamide (37.5 : 1)       4.93 ml 
10% SDS         0.15 ml 
10% Glycerol         0.15 ml 
10% APS         0.077 ml 
TEMED         0.0073 ml 
 
Stacking gel (5 ml for 2 gels) 
0.5 M Tris-HCl pH6.8       1.25 ml 
H2O          3 ml 
30% Acrylamide (37.5 : 1)       0.625 ml 
10% SDS         0.5 ml 
10% Glycerol         0.5 ml 
10% APS         0.015 ml 
TEMED         0.005 ml 
 
10 X Electrophoresis buffer (2 liter) 
Tris-Base         60.57 g 
glycine         288.27 g 
SDS          20 g 
H2O (top up)         2000 ml 
 
5X Transfer buffer for PVDF (1 liter) 
Tris-Base         60.57 g 
Glycine         72.07 g 
H2O (top up)         1000 ml 
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PBS solution (10 liter) 
NaCl          80 g 
Na2HPO4         11.6 g 
KH2PO4         2 g  
KCl          2 g 
Adjust pH to 7.2 – 7.4 
H2O (top up)         10 liter 
 
 
10X TBS (Tris-buffered saline) (1 liter) 
Tris-HCl pH7.5        121.4 g 
NaCl          90 g 
H2O (top up)         1000 ml 
 
Tris buffered saline-Tween 20 (TTBS) (2 liter) 
TBS          2000 ml 
Tween 20         1 ml 
 
Blocking buffer fore western blotting (100 ml) 
Non-fat milk powder or BSA      5 g 
TTBS          100 ml 
 
AP substrate solution (15 ml) 
25 × AP buffer        600 µl 
BCIP          150 µl 
NBT          150 µl 
H2O          14.1 ml 
 
HRP substrate solution (1ml) 
ECL reagent 1        0.5 ml 
ECL reagent 2        0.5 ml  
  
Stopping solution (ELISA) 
1 M H2SO4 
 
Reverse transcription cocktail (30 µl) 
AMV 5X buffer        6 µl 
dNTP buffer (10 mM)       1.5 µl 
Rnasin ribonclease inhibitor (40 U/µl)     0.75 µl 
AMV-reverse transcriptase (10 U/µl)     2 µl 
Random primer (3 µg/µl)       0.33 µl 
RNA          1 µl 
 189 
DEPC H2O (top up)        30 µl 
 
PCR reaction cocktail (25 µl) 
PCR master mix 2X        12.5 µl 
Upstream primer (10 µM)        1 µl 
Downstream primer (10 µM)      1 µl 
Nuclease Free H2O        9.5 µl 
cDNA template        1 µl  
 
Agarose gel solution (100 ml) 
Agarose powder        2 g 
1X TAE (0.04 M Tris-acetate and 0.001 M EDTA)   100 ml  
 
10X DNA loading buffer (20 ml) 
Bromophenol blue        0.025 g 
Xylene cyanol        0.025 g 
Glycerol         12.5 ml 
H2O          7.5 ml 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
